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ABSTRACT
Mixed Lineage Leukemia protein (MLL) is a key epigenetic regulator required for
proper embryonic development, and fetal and adult hematopoiesis. It is a SET domain
containing histone methyl transferase that trimethylates histone H3 on lysine 4
(H3K4Me3), a histone modification that correlates with active transcription. Like many
chromatin-associated proteins, MLL has multiplePHD fingers. Previous studies from our
laboratory have shown that the 3rd PHD finger of MLL interacts with the RNA
Recognition Motif (RRM) of Cyp33. Cyp33 is a Cyclophilin with peptidyl prolyl
isomerase (PPIase) activity. Over expression of Cyp33 results in transcriptional
repression of MLL target genes. Thus Cyp33 switches MLL from a transcriptional
activator to a repressor. In addition to binding to Cyp33, the MLL PHD3 also binds to
H3K4Me3. Thus MLL is an H3K4Me3 “writer” with an embedded “reader” for the same
mark. The aim of this study is to determine the biological function of MLL PHD3
binding to H3K4Me3 or Cyp33.
The in vitro binding studies performed by our collaborators, Sangho Park and
John Bushweller, have shown that Cyp33 binding to MLL PHD3 reduces the binding
affinity of the MLL PHD3 for H3K4Me3 by 5.7 fold. Therefore we sought to determine
the effect of Cyp33 on H3K4 trimethylation and on transcription of MLL target genes.
Cyp33 over expression resulted in a decrease in H3K4Me3 and H3Ac marks and increase
in recruitment of JARID1A and JARID1B, the H3K4 specific demethylases, at the MLL

xi

target gene promoters in a PPIase dependent manner. Also, shRNA- mediated down
regulation of JARID1B resulted in transcriptional activation of a sub-set of MLL target
genes. Thus we have identified JARID1B as transcriptional regulator of MLL target
genes.
To determine the transcriptional outcome of the MLL PHD3 binding to H3K4Me3
or Cyp33, we abrogated either H3K4Me3 binding or Cyp33 binding to the MLL PHD3
by point mutations in the MLL-N coding sequence and assessed the effect of expressing
the mutant proteins on MLL target gene expression. Over expressing wild type (wt)
MLL-N resulted in increased expression of a sub-set of MLL target genes, increased
recruitment of MLL-C and increased H3K4Me3 at MLL target gene promoters.
Abrogating Cyp33 binding resulted in transcriptional activation of MLL target genes,
however the effect was similar to that of wt MLL-N over expression. Unlike MLL-N wt ,
abrogation of H3K4Me3 binding to the MLL PHD3 did not result in transcriptional
activation of MLL target genes, did not show an increase in MLL-C recruitment and did
not increase H3K4Me3 levels. Also, abrogation of MLL PHD3 binding to H3K4Me3
resulted in decreased expansion of mouse hematopoietic progenitors in a methyl cellulose
colony formation assay when compared to wt MLL-N. This indicates that the MLL
PHD3 binding to H3K4Me3 contributes to the transcriptional activation of MLL target
genes in hematopoietic progenitors. Thus, MLL PHD3 binding to H3K4Me3, contributes
to the expansion of hematopoietic progenitors, demonstrating the biological significance.
Taken together, the transcriptional outcome of MLL target genes is influenced by Cyp33

xii

and H3K4Me3, the ligands of MLL PHD3. Therefore the MLL PHD3 serves as a ligand
regulated molecular switch influencing the transcription of MLL target genes.

xiii

CHAPTER 1
INTRODUCTION
The MLL protein is a Trithorax group transcriptional regulator that is
evolutionarily conserved throughout metazoans 1. It belongs to the MLL family of SET
domain containing histone methyl transferases which methylate histone H3 on lysine 4 2–
5

. The H3K4Me3 mark at gene promoters is associated with active transcription. In

addition to its histone methyl transferase activity, MLL is a multi-domain containing
protein. The domains of MLL allow it to associate with DNA, other chromatin regulators
and histone modifiers, making it a versatile and a key epigenetic regulator.
MLL (MLL wt) is required for fetal and adult hematopoiesis and for embryonic
development 6,7. It is required for the maintenance of H3K4Me3 marks at Hox gene
promoters 3. Hox genes are a cluster of conserved, homeo-box containing transcription
factors, responsible for the proper segmental identity during embryonic development and
for the maintenance of tissue-specific developmental programs in adults 8. In addition to
its known role in embryonic development and hematopoiesis, MLL is also a cell cycle
regulator. Cell cycle promoters of E2F target genes and cell cycle inhibitors like
CDKN1A and CDKN1B are known targets of MLL 9–11.
Chromosomal rearrangements of the MLL gene are a frequent phenomenon in
mixed lineage leukemia, hence the name MLL for the gene and protein 12,13.The MLL
fusion proteins constitutively activate the transcription of a sub-set of MLL target genes
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2
resulting in increased self-renewal of hematopoietic progenitors, keeping them in an
undifferentiated state and eventually leading to leukemogenesis 14–16. MLL rearranged
leukemia are aggressive, are often associated with poor prognosis and the available
treatments do not increase the survival of the patient significantly 17–19. In MLL
rearranged leukemia, only one of the MLL alleles is rearranged, the other allele is intact,
and recent studies have demonstrated that MLL fusion protein requires the co-expression
of the wild type MLL (MLL wt) for MLL fusion mediated transformation and
leukemogenesis 20. To design successful treatments for MLL rearranged leukemia one
must know the relevant functions and contribution of MLL wt in leukemogenesis. MLL
fusion proteins lacks PHD fingers, a bromo-domain, an activation domain and the SET
domain, but retain the N-terminal region of MLL through the repression domain 21,22 .
Studies from our laboratory (Chen et al., 2008) and from another group (Muntean et al.,
2008) have shown that inclusion of the MLL PHD3 in a MLL fusion protein blocks MLL
fusion mediated transformation of hematopoietic progenitors. Our present study focuses
on understanding the role of MLL PHD3, and its ligands, in transcriptional regulation of
MLL target genes.
Previous studies from our lab have shown that the RRM (RNA Recognition Motif)
domain of Cyp33 is a ligand for MLL PHD3 23. Over expression of Cyp33 causes
transcriptional repression of MLL target genes. Cyp33 belongs to the cyclophilin family
of proteins. The RRM of Cyp33 binds AU rich RNA, is known to be present in
spliceosomes and is involved in pre- mRNA splicing 24. The cyclophilin domain of
Cyp33 possesses Peptidyl Prolyl Isomerase (PPIase) activity which facilitates the cistrans conformation change of prolyl peptide bonds 25. 23 Double point mutations in the

3
Cyclophilin domain of Cyp33, R191A and F196A resulted in at least 99% reduction in
the cis-trans proline isomerization (Wei, Breslin, Schultz, and Diaz, unpublished). The
PPIase activity of Cyp33 is critical for the transcriptional repression of MLL target genes
26

.
Over expression of Cyp33 augmented the recruitment of the transcriptional co-

repressors HDAC1 and Bmi-1 27. MLL fusions lack PHD3 and are resistant to Cyp33
mediated repression of MLL target genes. The inclusion of the MLL PHD3 in MLL-ENL
fusion proteins enabled the fusion proteins to interact with Cyp33 and recruit HDAC1 to
the repression domain of MLL resulting in decreased expression of MLL target genes. As
a consequence, the MLL fusion mediated transformation of mouse hematopoietic
progenitors was blocked by inclusion of MLL PHD3 in MLLfusion28.
Another ligand that binds MLL PHD3 is H3K4Me3. Recently, we and others have
reported that the MLL PHD3 present in MLL-N, binds to H3K4Me3 26,29,30. The MLL
PHD3 is a small domain of 60 amino acids. The Cyp33 binding site and H3K4Me3
binding sites are very close to each other. Hence binding of one ligand may affect the
binding of the other. Furthermore, results from in vitro binding studies performed by our
collaborators (Park and Bushweller) have revealed that the presence of Cyp33 increased
the Kd (dissociation constant) for MLL PHD3 binding to H3K4Me3 by 5.7 fold. Thus
Cyp33 reduces the affinity of MLL PHD3 for H3K4Me3 26. If this is true in vivo, then an
excess of Cyp33 would be predicted to affect the binding of MLL PHD3 to H3K4Me3.
As a consequence, the H3K4Me3 marks would be exposed to histone demethylases
resulting in demethylation of H3K4Me3 at MLL target genes promoters. The presence of
the H3K4Me3 mark at MLL target gene promoters is associated with open chromatin and
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transcriptional activation. Therefore a decrease in H3K4Me3 would result in decreased
target gene expression. This hypothesis was tested by studying the effect of Cyp33 over
expression on H3K4 trimethylation at MLL target genes. Cyp33 over expression results
in increased recruitment of JARID1 histone demethylases and a corresponding decrease
in H3K4Me3 levels at MLL target gene promoters. Thus this study has identified another
mechanism of Cyp33-mediated transcriptional repression of MLL target genes.
JARID1 family proteins are histone H3K4Me3 specific demethylases 31–34.
Among the JARID1 family proteins, JARID1A and JARID1B have three PHD fingers.
The PHD3 of JARID1A and JARID1B are known to bind to H3K4Me335. They are
H3K4Me3 “erasers” with an embedded “reader” for H3K4Me3 and therefore, can bind to
H3K4Me3 and demethylate H3K4Me3 in adjacent histones or nucleosomes.
MLL is a “writer” with an embedded “reader”. Nevertheless, the writer and reader
functions are imparted by two separate protein fragments of MLL. The MLL protein is
proteolytically cleaved into an N-terminal (MLL-N) and a C-terminal (MLL-C)
fragments by the protease TASPASE-1 36. The PHD3 that binds to H3K4Me3 (“reader”)
is present on MLL-N, while the SET domain (“writer”) is present on MLL-C. MLL-N
and MLL-C interact directly through their FYRN and FYRC domains, and this
interaction protects MLL-N from degradation by the E3 ubiquitin ligase SCF Skp 37. The
nuclear localization signal in MLL-N is required for nuclear translocation of MLL-C.
Thus the two different fragments require each other for functional holo-complex
formation at the MLL target gene promoters 38. Furthermore, the MLL-N and MLL-C
interaction brings the reader and writer of H3K4Me3 together in the same complex.
Hence we proposed that the MLL PHD3 binding to H3K4Me3 may help MLL-C to
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methylate histone H3K4 on adjacent nucleosomes and also protect the methylated lysine
4 from histone demethylases, resulting in transcriptional activation of MLL target genes.
Additionally, the activation domain of the MLL-C associates with histone acetyl
transferases (HATs) like CBP and p300 39. The acetylation of histones opens the
chromatin and allows the DNA to be accessible to transcription factors and the basal
transcription machinery. The acetylation of histones is associated with transcriptional
activation. MLL PHD3 binding to Cyp33 enhances the recruitment of transcriptional
repressors like HDAC1 (Histone Deacetylase) and Bmi-1 leading to transcriptional
repression of MLL target genes. For all the above mentioned reasons, we hypothesized
that the MLL PHD3 binding to H3K4Me3 versus Cyp33 may have opposite effects on
the transcriptional outcome for MLL target genes. Therefore, we wanted to determine the
effect of abrogation of MLL PHD3 binding to H3K4Me3 or to Cyp33 on the transcription
of MLL target genes in mouse embryonic fibroblasts (MEFs) and in primary mouse
hematopoietic progenitors.
The point mutations that disrupt MLL PHD3 binding to H3K4Me3 or Cyp33 were
introduced in the PHD3 encoding region of MLL-N. MLL-N wt or its mutants were over
expressed in MEFs or in mouse hematopoietic progenitors and the effects on transcription
of MLL target genes and on colony formation by hematopoietic progenitors was studied.
Interestingly, over expression of MLL-N wt without over expressing the MLL-C resulted
in increased H3K4Me3 marks, increased recruitment of MLL-C and increased
transcriptional activation of a sub-set of MLL target genes. On the other hand, abrogation
of MLL PHD3 binding to H3K4Me3 resulted in decreased H3K4Me3 marks and MLL-C
recruitment at MLL target gene promoters, as well as decreased expression of a sub-set of
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MLL target genes. More importantly, abrogation of MLL PHD3 binding to H3K4Me3
resulted in a drastic decrease in colony formation of primary mouse hematopoietic
progenitors indicating a defect in their proliferation. The abrogation of MLL PHD3
binding to Cyp33 resulted in transcriptional activation of a sub-set of MLL target genes;
however, the effects were similar to that of MLL-N wt over expression.
As mentioned earlier, recent studies have implicated the Mll wt allele in
leukemogenesis and transformation of Mll fusion mediated leukemia. Milne et al., have
shown that the MLL fusion protein binds to the Hoxa9 promoter only when the promoter
is already bound by the MLL wt protein. They identified the repression domain and PHD
fingers as the minimal regions in MLL wt that contributes to the targeting of the MLL
fusion to the Hoxa9 promoter. Mutation of the PAF binding site in the repression domain
and the H3K4Me3 binding site in the MLL PHD3 affected the MLL fusion’s ability to
bind to its target promoters40. Results from this study show that abrogating H3K4Me3
binding or Cyp33 binding to MLL PHD3 did not have any effect on MLL-AF9 mediated
transformation of hematopoietic progenitors in a serial plating methyl cellulose colony
formation assay. However, the effect of abrogation of H3K4Me3 binding of the MLL
PHD3 on cell transformation by other MLL fusions has yet to be determined.
In conclusion, MLL PHD3 binding to H3K4Me3 contributes to H3K4
trimethylation, followed by transcriptional activation of a sub-set of MLL target genes
and colony formation by hematopoietic progenitors. Additionally, we have identified a
link between the JARID1 histone demethylases and Cyp33 mediated transcriptional
repression of MLL target genes. Thus, the ligands of the MLL PHD3 influence the
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transcription of MLL target genes and act as a molecular switch for transcriptional
regulation of MLL target genes.

CHAPTER 2
REVIEW OF LITERATURE
Mixed Lineage Leukemia
Mixed Lineage leukemia is a distinct molecular sub-type of acute leukemia that
occurs as a result of the chromosomal rearrangement of the 11q23 region. In these MLL
rearrangements, the 11q23 chromosomal breakpoint region falls within the MLL gene and
since this cytogenetic abnormality is found in both acute myeloid or acute lymphoid
leukemia, often with lineage infidelity (expression of some markers of the opposite
lineage), the gene is named after the disease 12. The translocation of MLL with another
gene results in an in-frame fusion gene that encodes for the leukemogenic MLL fusion
protein. So far, there are 100 different recurrent MLL translocations reported, with at least
60 different partner genes 41. MLL-rearranged leukemia accounts for 70% of all ALL and
35-50% of all AML in infants. In older children and adults it accounts for about 10% of
all leukemia. Patients with MLL- rearranged leukemia show poor prognosis. The more
common fusion partners of MLL are AF4, AF9, ENL, AF10, AF6, ELL, AF17, and
SEPT6 which altogether account for 90% of MLL-rearranged leukemia 42.
Besides chromosomal rearrangement, gene amplification and partial tandem
duplication (PTD) of MLL are other mechanisms of deregulation of MLL that occur
frequently in acute leukemia. About 3- 20 copies of the entire MLL gene are found in the
leukemic cells of older patients with acute leukemia or myelodysplatic syndrome 43. The
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exons 11-5 or 12-5 of the MLL gene are duplicated in the PTD of MLL. MLL PTD retains
the TASPASE1 cleavage site and C-terminal histone methyl transferase activity. About
4-7% of AML patients have MLL PTD 44.
Domains of MLL Protein
MLL is a very large, 431 kDa protein with many different identified domains that
mediate protein-DNA, protein-protein, or protein-RNA interactions. The MLL protein is
proteolytically cleaved into an N- (MLL-N) and a C-terminal (MLL-C) fragment by the
protease TASPASE1 36. The MLL-N fragment has a Menin binding region, 3 AT hooks,
a repression domain, 4 PHD fingers, an atypical bromo domain and a FYRN
(Phenylalanine and Tyrosine Rich N-terminus) domain. The MLL-C fragment has the
transcriptional activation domain, a FYRC (Phenylalanine and Tyrosine Rich C-terminus
domain). The chromosomal break point region is just before PHD112. Hence the fusion
protein contains a portion of MLL N-terminus through the repression domain fused inframe with a C- terminal partner protein fragment. The rest of the N-terminus (from the
PHD finger region to the TASPASE1 cleavage site) and the whole of MLL-C fragment is
deleted in the MLL fusion protein as shown in Figure 1. Nevertheless, the deleted regions
are frequently, but not always, represented in the reciprocal translocation product.
The first 43 amino acids of the N-terminus of MLL contains the Menin binding
site45. Menin enhances the localization of MLL to its target promoters, is required for
MLL’s histone methyl transferase activity and thus for the MLL target gene expression
46,47

. Furthermore, Menin brings in other oncogenic factors like LEDGF and c-Myb to

MLL and is essential for MLL fusion mediated leukemogenesis 48,49.
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The MLL AT hooks, similar to the ones present in the HMG group proteins, bind
AT-rich DNA sequences. However, the AT hooks of MLL do not recognize DNA in a
sequence specific manner. Instead, they recognize and bind to cruciform DNA structures
21

. This region of MLL also is also a mediator of an interaction with the SET onco-

protein, and with GADD34 50,51. The first 1,100 amino acids of MLL-N are required for
MLL localization in a punctate distribution in the cell nucleus. Specifically, the SNL1
and SNL2 regions present in the N-terminal region of MLL contribute to the sub-nuclear
localization of MLL 52.
The repression domain of MLL recruits transcriptional co-repressors like
HDAC1, hPC2, Bmi-1 and CtBP 27. Part of the MLL repression domain encodes the
CXXC domain which binds to non-methylated CpG on the DNA 53. Through this
property, MLL protects CpG dinucleotide sequences from DNA methylation 54. Recent
studies have shown that the repression domain of MLL recruits PAF1, a member of the
PAF-C transcriptional elongation complex, to MLL target gene promoters and is required
for the MLL fusion mediated leukemogenesis and transformation 55.
There are three tandem PHD fingers and an atypical extended PHD finger in
MLL. This region of MLL is highly conserved from Drosophila to humans. The PHD
fingers of MLL homodimerize; however, the significance of homo-dimerization is yet to
be determined 23. The first and fourth PHD fingers of MLL contribute to the interaction
between the MLL-N and MLL-C fragments 38. A recent study has shown that the second
PHD finger of MLL has an E3 ligase activity and requires the E2 ubiquitin conjugating
enzyme CDC34 for its activity. Histones H3 and H4 were identified substrates of
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ubiquitination in vitro. The PHD2 E3 ligase activity negatively regulates MLL target
gene expression 56.
The third PHD finger of MLL is the region of interest of this study. Yeast two
hybrid studies performed in our laboratory identified Cyp33 as a ligand for the MLL
PHD3. Cyp33 over expression augmented the recruitment of the transcriptional
repressors like HDAC1 and Bmi-1, to the repression domain and resulted in
transcriptional repression of MLL target genes 23. The PHD3 of Trithorax (TRX), the
Drosophila homologue of MLL, also binds to Drosophila Cyp33 57. All the PHD fingers
are deleted in leukemogenic MLL fusions. The insertion of the MLL PHD3 in a MLLENL fusion protein, enabled the fusion protein to interact with Cyp33 and recruit HDAC
to the repression domain of MLL, resulting in decreased expression of MLL target genes
28

. Thus , the wild type MLL responds to transcriptional activation or transcription

repression cues and switches on or off target genes expression. But the MLL fusions are
resistant to the mechanisms of transcription repression and constitutively activate the
target genes. Similar to other PHD finger containing chromatin-associated proteins,
PHD3 of MLL binds to trimethylated H3K4 26,29,30. The binding of MLL PHD3 may
contribute to the transcriptional activation of MLL target genes. The MLL fusion protein
binds to the target promoters that are already bound by wild type MLL. MLL PHD3
binding to H3K4Me3 and PAF1 binding to the repression domain cooperate to recruit
MLL wt to the target promoter 40.
A short amino acid sequence between the PHD4 and the bromo-domain of MLL
is required for interaction with HCF1, a cofactor of E2F1. This interaction recruits MLL
to E2F responsive promoters 9. The bromo-domain of MLL is an atypical one and does
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not bind acetylated lysine, however its interaction with the MLL PHD3 increases the
affinity of the latter for H3K4Me329. The FYRN domain of MLL is a phenyl alanine and
tyrosine rich region in the N-terminus which interacts with the FYRC region present in
the C-terminus, thus tethering the MLL-N and MLL-C fragments together (Figure 2)36.
The transcriptional activation domain of MLL-C binds to histone acetyl
transferases like p300 and CBP 39. The region adjacent to the activation domain interacts
with the H4K16 acetyl transferase MOF and this interaction contributes to the
transcriptional activation of HOX genes 58. The SET domain of MLL is the catalytic
domain that possesses the histone methyl transferase activity. The SET domain requires
other core components of the COMPASS-like complex, RbBP5, ASH2L, WDR5 and
DPY-30 to trimethylate histone H3 on lysine 4 59.
The SET domain has been reported to play a role in homo-dimerization and single
stranded DNA and RNA binding 60,61. The domains of MLL act as platforms for both
homo and hetero-molecular interactions empowering MLL to be a key epigenetic
regulator.
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Figure 1: Illustration of domains of MLL wt and MLL fusion proteins.

MLL wt is proteolytically cleaved into MLL-N and MLL-C fragments by
TASPASE1. Both MLL wt and the fusion have AT hooks, the Sub-Nuclear
Localization (SNL) 1 and 2, repression domain (RD). The chromosomal break point
region is just before or within the PHD1. Hence the region including the PHD fingers,
the bromo-domain, the FYRN domain, the Activation domain (AD) and the SET
domain is not present in the fusion proteins. MLL wt is a writer with an embedded
reader. The SET domain is a histone methyl transferase that trimethylates histone H3
on lysine 4. The PHD3 is the reader that recognizes H3K4Me3 marks.
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Figure 2: The hetero-dimerization of MLL-N and MLL-C allows the writer and
reader to be present in the same complex.

MLL is a writer with an embedded reader for H3K4Me3. The SET domain of MLL is
a histone methyl transferase that trimethylates histone H3 on lysine 4, hence it is a
writer. The PHD3 of MLL binds to H3K4ME3; hence it is a reader of H3K4Me3.
Though the writer and reader functions are present in the same protein, due to
proteolytic cleavage by TASPASE1 they are separated in two different polypeptides.
The proteolytic cleavage of MLL by TASPASE1, results in a 320 kDa MLL-N
fragment and a 180 kDa MLL-C fragment. The MLL-N and MLL-C interact through
their FYRN and FYRC domains. This interaction protects MLL-N from degradation
and also is required for nuclear localization of MLL-C. Also, allows the writer and
reader to be present in the same complex.
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Post Translational Regulation of MLL
MLL is proteolytically cleaved by TASPASE1 and this cleavage is essential for
the histone methyl transferase activity of MLL and transcription regulation of MLL target
genes. The nuclear localization signal in MLL-N is required for nuclear translocation of
MLL-C. MLL-N is targeted for degradation during the S and M phases of the cell cycle
by SCF Skp and APC Cdc20 E3 ligases 37. The interaction of MLL-N and MLL-C stabilizes
MLL-N and protects it from degradation. The MLL-C protein that is not bound to MLLN cannot enter the nucleus and is targeted for proteasome-mediated degradation in the
cytoplasm. Thus the two fragments require each other for formation of the functional
enzymatically active holo-complex at target gene promoters 38. Furthermore, MLL-N and
MLL-C interaction brings the reader and writer of H3K4Me3 together in the same
complex as shown in Figure 2. MLL fusions do not have the TASPASE1 cleavage site;
hence they are resistant to cell cycle specific degradation. MLL is phosphorylated at Ser
516 by ATR. This phosphorylation event is a response to DNA damage and is required
for correct execution of the S-phase check point. Phosphorylation at Ser 516 disrupts the
interaction with SCF Skp and protects MLL from degradation. The accumulated MLL then
methylates the histone H3K4 at the late replicating origins, and inhibits CDC45 loading,
thus delaying DNA replication. The MLL fusion gets phosphorylated at Ser 516 but lacks
the SET domain, hence resulting in a dysregulated S phase check point 62.
Molecular Complexes Containing MLL
The very first immunoaffinity purification of MLL complex was performed by
Nakamura et al. That study identified MLL is present in complex with 28 other proteins.
Other notable proteins of this complex are global transcription regulators that belong to
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the core transcriptional machinery like TFIID and TBP; ATP-dependent nucleosome
remodeling proteins like SWI/SNF, NuRD (HDAC), hSNF2H and Sin3A (HDAC); and
other core components of the yeast Set1 histone methyl transferase complex like RbBP5
and WDR5. Though MLL is generally considered as the transcriptional activator, in this
complex it was present along with transcriptional repressors like HDAC. More
interestingly, except for MLL, there are no other Trithorax group proteins present in the
complex.
Yokoyama et al. biochemically purified MLL along with the core components of
SET1 like, complex. The proteins present in the complex are RbBP5, ASH2L, WDR5
and DPY-30. The SET domain of MLL is not intrinsically active for the H3K4 methyl
transferase activity. These proteins are required for the substrate recognition and
enzymatic activity of the MLL SET domain and thus for the transcriptional activation of
MLL target genes. Additionally, this protein also contains HCF1 and Menin. In contrast
to the super-complex identified by Nakamura, this 1MDa complex is much smaller in
size and is made exclusively of transcriptional activators 59.
Biological Functions of MLL
MLL belongs to the Trithorax group (trx-G) proteins that are positive
transcriptional regulators, which antagonize the function of Polycomb (PcG) mediated
transcriptional repressors 63. The trx and Pc-G proteins, which maintain the identity of
cells by keeping the target genes active or silent respectively are key components of the
epigenetic mechanisms that dictate cell fate determination 64. The TRX mutants in
Drosophila show anterior or posterior segmental transformations65. Yu et al. generated
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Mll hypomorph mice by inserting promoter less lacZ in the third exon of Mll. The
homozygous deletion of Mll (Mll-/-) is embryonically lethal at around day 10.5. Hox
genes are expressed in Mll-/- mice until day 9.5, but their expression was not maintained
any further, showing that Mll is required for the maintenance rather than initiation of
Hox gene expression. Mice heterozygous for Mll (Mll+/-) were smaller in size, anemic
and had defects in the axial skeleton, disordered segmental identities of cervical, thoracic
and lumbar regions; highlighting the importance of MLL in development and
hematopoiesis 8. Mice with homozygous deletion of the SET domain of Mll also have
altered body segments, decreased H3K4 mono methylation and decreased Hox gene
expression 66. The altered segment phenotypes are features of homeotic transformation,
mirroring the phenotype of Trx mutations in Drosophila. Furthermore in mammals, Mll is
required for normal hematopoiesis, skeletal and neural development. Mll-/- yolk sac and
fetal liver have reduced cellularity and the hematopoietic progenitors from fetal livers
show decreased expansion in methyl-cellulose colony formation assays 6. This showed
that Mll is critically required for fetal hematopoiesis, specifically required for the fetal
HSC self-renewal. Using a conditional knock out of Mll, McMahon et al. showed that
Mll is also required for self-renewal of HSCs postnatally 67.

Transcriptional Targets of MLL
Genome wide MLL occupancy and in vivo mouse studies and have been
undertaken to identify the targets of MLL. Several studies have shown that MLL binds to
a specific set of target gene promoters and through its intrinsic histone methyl transferase
activity; and associated acetyl transferase activities activates the transcription of these
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target genes. However, genome wide ChIP on chip for human MLL performed by
Guenther et al. showed that 90% of RNA PolII bound promoters of actively transcribing
genes were also bound by MLL. Furthermore 92% of MLL-bound promoters showed
enrichment for H3K4Me3 suggesting a global role for the histone methyl transferase
function of MLL in transcription. Interestingly, the findings from this study showed MLL
occupancy and H3K4 trimethylation at HOX genes like HOXA7, HOXA9, HOXA10,
HOXA11 and HOXA13 was not just limited to the transcription start site and 5’ region of
the gene. Instead the chromatin was extensively occupied by MLL both upstream and
downstream of the genes, and this binding correlated with active transcription of the
genes. This was also shown for another MLL target gene Meis1 68. Milne et al. showed
that the C-terminus of MLL interacts with the Ser5 phosphorylated RNA polII CTD
suggesting a global role for MLL in transcription. However, they also showed that MLL
occupied only a subset of actively transcribing genes. ChIP performed for Mll and Ser5
phosphorylated CTD in MEFs and showed that they co-localized at Mll target genes like
Hoxa9 and Hoxc8 69.
In striking contrast to Guenther et al.’s finding, a genome wide ChIP on chip
performed by Wang et al. in Mll +/+ and Mll-/- MEF showed that only 5% of promoters
showed a Mll-dependency for H3K4 trimethylation. In agreement with a majority of
studies in the MLL field, this study also identified a sub-set of Hox genes like Hoxc8,
Hoxc9 and Hoxc6 as Hoxc5, Hoxb4, Hoxb6, Hoxb10, Hoxa6, Hoxa7, and Hoxa9 as key
MLL target genes. Moreover, MLL and MLL4 (also called MLL2) show some level of
redundancy in regulating the transcription of their targets. Additionally, this study also
identified that a major fraction of the MLL target genes are transcription factors and also
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identified a couple of novel targets in the Wnt signaling pathway which in turn regulate
the transcription of Hox genes 70.
Though the genome wide studies for the target genes of MLL show some
contradictions, the in vivo studies from Mll mutant or knockout mice studies have clearly
demonstrated Hox-specific phenotypes. Hox genes code for evolutionarily conserved
homeo-domain containing transcription factors. There are 39 Hox genes in mammals,
arranged in four clusters (A to D) present in four different chromosomes. They are
required for positional identity of body segments along the anterio-posterior axis of the
body 71. Hence they have a pivotal role in fetal development and embryogenesis. Hoxa5,
Hoxa7, Hoxa9, Hoxa10, Hoxb3, Hoxb6 and Hoxc8 are the Hox genes that have been
shown to be critical for hematopoietic stem cell (HSC) self-renewal 72. Though many Hox
genes are required for normal hematopoiesis, a few Hox genes like Hoxa9, Hoxa7 and
Hoxa10 are over expressed in MLL-rearranged leukemia and are necessary for the
leukemic transformation of hematopoietic progenitors.
Meis1 is another MLL target gene that encodes for a TALE (Three Amino acid
Loop Extension) sub-type of homeo-box containing transcription factor 68,69. Unlike Hox
genes, the Meis family genes are non-clustered. Meis1 collaborates with Hox9-13 to bind
DNA 14. It is over expressed along with Hoxa9 in MLL-rearranged leukemia and cooperates with Hoxa9 in leukemic transformation of hematopoietic progenitors 15.
RUNX1 (AML1) is another gene that is frequently rearranged in AML leukemia.
Like MLL, the RUNX1 protein is also required for normal hematopoiesis. Recently
Huang et al., identified that an MLL interaction with the N-terminus of RUNX1 protects
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RUNX1 from ubiquitin mediated proteosomal degradation. Moreover, MLL is required
for maintenance of H3K4 trimethylation at the promoter of RUNX1 target genes like
PU.173. Besides Hox genes, cell cycle regulators like Myc and E2F1 target genes are also
targets of MLL. Using a Taspase1-/- mice, Hsieh et al. demonstrated that proteolysis of
MLL is required for transcriptional regulation of its targets. Taspase1-/- mice showed
homeotic phenotype similar to Mll mutant mice, in addition, the Taspase1 null mice were
smaller in size. Furthermore, this study identified E2F target genes as transcriptional
targets of MLL, highlighting a role for MLL in cell cycle regulation 74. MLL is also a
transcriptional regulator of cell cycle inhibitors like Cdkn1a and Cdkn1b 10,11.

Chromatin Accessibility and Histone Modifications
The human genome is made of more than 3 billion base pairs. To fit into a cell
nucleus that is about 2µm in diameter, DNA has to be compacted at least 10,000 fold.
This is made possible by wrapping of DNA around histones75. An histone octamer made
from four different histones: H3, H4, H2A and H2B. About 146 bp of DNA are wrapped
around a histone octamer forming a mononucleosome. Each mono nucleosome is
connected to another by a linker histone, this arrangement or packaging fashion is
referred to as beads on a string model which further coil helically to form a higher order
solenoid in which the diameter of the chromatin fiber is 30 nm 76,77. Though histones are
very useful in compaction of DNA, they limit the accessibility of DNA for various DNAtemplated cellular processes like transcription, DNA replication, DNA damage-response
repair, recombination etc 78,79. Chromatin associated proteins are key modulators of DNA
accessibility. Post translational modifications of histone tails, exchange of core histones
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for histone variants, sliding of nucleosomes by nucleosome remodeling complexes are the
mechanisms that regulate the accessibility of DNA to regulatory proteins.
A portion of the amino terminal region of core histone proteins protrudes from the
nucleosome, and is accessible to histone modifying enzymes. Post translational histone
modifications act as docking sites for proteins that recognize the histone code and recruit
other effector proteins 80. The enzymes that post translationally modify the histones are
referred to as writers. The proteins that recognize the modifications are referred to as
readers. The proteins that remove the modifications are referred to as erasers. The basic
amino acids like lysine and arginine in histones can be methylated. Additionally, lysines
can be acetylated or ubiquitinated. The serines and threonines can be phosphorylated.
The effect of histone modification on transcription is very well studied. The
transcriptional outcome depends on the amino acid modified, the histone tail the amino
acid is present in (H3, H4, H2A and H2B), and the nature of the modification 81.
Acetylation of lysines in histones is considered as a transcriptional activation mark
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HATs like p300, CBP, and MOF are the enzymes that acetylate the lysines on histones,
and the mark is removed by histone deacetylases ( HDACs Class I, II and III) 83,84.
Acetylated lysines are recognized by bromo-domain containing proteins85.
Histone methyl transferases; mono-, di- or trimethylate lysines on histones and
have a SET (an acronym framed from the histone methyl transferases in Drosophila
Su(Var)39, Enhancer of Zeste and Trithorax) domain as the catalytic domain. Some
lysine methylation like H3K4Me3 is correlated with active transcription, whereas
H3K9Me3 and H3K27Me3 are correlated with gene repression. The chromodomain,

22
Tudor domain, WD-40 repeat and PHD fingers recognize methylated lysines 85. The Set1
enzyme found in yeast mono-, di-, and tri-methylates histone H3K4. SET1A and SET1B
MLL, MLL2, MLL3, and MLL4 are the H3K4 specific histone methyl transferases in
mammals4. The mammalian histone demethylase that demethylates mono- and dimethylated H3K4 is LSD1.The mammalian demethylases JARID1A, JARID1B,
JARID1C and JARID1D demethylates mono-, di-, and tri-methyl histone H3K4 86.

Cyp33 and H3K4Me3- The Known Ligands of MLL PHD3
The known ligands of MLL PHD3 are Cyp33 and H3K4Me3 (Figure 3A).
Structural and NMR studies of MLL PHD3 binding to Cyp33 or H3K4Me3 were
characterized by three different groups 26,29,30,87. The in vitro binding studies from our
collaborators Sangho Park and John Bushweller and from another group, have shown
that Cyp33 has a higher binding affinity for MLL PHD3 than H3K4Me3 26,30,87.
Isothermal calorimetry studies show that the MLL PHD3 binds to Cyp33 RRM with a
kDa of 14.7 µM while the kDa for H3K4Me3 is 30.9 µM. Cyp33 and H3K4Me3 bind to
two distinct surfaces of the MLL PHD3 but they are very close to each other. The effect
of RRM of the Cyp33 on MLL PHD3-H3K4Me3 complex formation and vice versa
shows that the interactions are mutually inhibitory 26. The hydrophobic residues present
on the α1 and α2 helices and on the loop 4 of the MLL PHD3, projects into the groove of
β sheet of the Cyp33 RRM. This interaction is primarily mediated by hydrophobic
residues V1617, Y1619, M1606, I1609 and L1610 in the MLL PHD3 and V7, Q36, F51,
D53 and A82 in the Cyp33 RRM as shown in Figure 3B.
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Figure 3: Ligands of MLL PHD3.

A, Schematic of MLL PHD3 binding to Cyp33 or H3K4Me3; B, A ribbon representation
of the interaction of MLL PHD3 (blue) and Cyp33 RRM (magenta). The residues that are
involved in the interaction in MLL PHD3 are in green and in Cyp33 RRM are in yellow.
C, Crystal structure showing the hydrogen bonds between MLL PHD3 (blue) and bound
H3K4Me3 peptide (yellow). This figure is from Z.Wang et al. Cell, 2010.
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The high affinity interaction of the MLL PHD3 with the RRM of Cyp33 is inhibited by
linking the MLL PHD3 to bromo-domain of MLL. However, this inhibition is overcome
by adding the PPIase domain of Cyp33. The PPIase activity of Cyp33 targets the P1629
present in the linker region between the MLL PHD3 and the bromo-domain resulting in a
conformational change that allows of the binding of MLL PHD3 to the RRM of Cyp33 29.
The above mentioned finding is from in vitro binding studies. The importance of
isomerization of P1629 on Cyp33 binding is yet to be demonstrated in a cellular system.
Similar to other PHD fingers that bind H3K4Me3, the MLL PHD3 also forms an
aromatic cage that act as a binding module for the trimethyl ammonium group of K4Me3.
The interaction is primarily mediated by Y1576, Y 1581, M1585 and W 1594 in the MLL
PHD3. The binding of the MLL PHD3 to H3K4Me3 results in a conformational change
in the loop segment between Y15756 to M1585A resulting in a conformational change
that burries the methyl side chain of H3K4 in the aromatic cage. Moreover Wang et al.
have shown that the bromo domain of MLL also contributes to the recognition of
H3K4Me3 29. The MLL PHD3 interacts with the extended helix of the bromo-domain of
MLL. In the absence of the interaction between MLL PHD3 and bromo domain only a
partial aromatic cage is formed. The binding of the MLL PHD3 to H3K4Me3 contributes
to the transcriptional activation of MLL target genes however the biological significance
of this binding has yet to be determined.
Cyp33 and its Functions
Cyp33 is a 33 kDa, RNA binding cyclophilin family protein. It was first identified
in 1996 from human T-cells 25. It contains an RNA recognition motif (RRM) and a
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Cyclophilin domain. The Cyclophilins are cyclosporin A binding proteins 88. To date
there are at least 16 cyclophilins identified in humans. All the cyclophilins have the
prolyl isomerase activity. The proline in the peptide bond exist mostly in cis
conformation, this is the restricted conformation. The peptidyl prolyl isomerase catalyzes
the cis-trans prolyl isomerization of the prolyl bond and thus assisting in the proper
folding of the protein 89. Due to its peptidyl prolyl isomerase activity Cyp33 is also called
PPIE or Cyclophilin E. The RRM of Cyp33 binds to poly-A or poly-U containing RNA.
Cyp33 is a component of spliceosome and is involved in pre-mRNA splicing 24. Besides
binding RNA, the RRM of Cyp33 binds to proteins. Previous studies from our lab have
shown that the RRM of human Cyp33 directly binds to the 3rd PHD finger of human
MLL, and the interaction is not mediated by RNA binding. Moreover, the interaction
between the Cyp33 and MLL PHD3 disrupts the interaction between Cyp33 and RNA 87.
Over expression of Cyp33 resulted in increased recruitment of transcriptional corepressors like HDAC1 and Bmi-1 to the repression domain of MLL resulting in
repression of MLL target genes 23,27. More importantly this interaction is evolutionarily
conserved and occurs in Drosophila. Dcyp33 binds to the third PHD finger of Trithorax,
a Drosophila homologue of human MLL. Also, over expression of Dcyp33 in Drosophila
SL1 cells resulted in down-regulation of the Trithorax target genes, highlighting the
evolutionarily conserved role of Cyp33 in transcriptional regulation 57.

26

Figure 4: Illustration of Protein Domains of Cyp33.

The N-terminal RRM domain of Cyp33 can bind to RNA and also mediates the
interaction of MLL PHD3 and Cyp33. The Cyclophilin domain of Cyp33
contains prolyl isomerase activity. The region between the RRM and the
Cyclophilin domain partially conserved and is known as the spacer region. The
function of this region is unknown.
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Furthermore, the PPIase activity is required for Cyp33 mediated transcriptional
repression of MLL target genes 26,29. Though Cyp33 was identified as a prolyl isomerase
in 1996, until recently the targets of the Cyp33 PPIase activity were not known. Wang et
al., recently demonstrated that the proline1629 present in the linker region between PHD3
and the bromo-domain of MLL is a target of the Cyp33 PPIase activity. The cis-trans
isomerization of proline 1629 resulted in drastic conformational change allowing MLL
PHD3 to bind to RRM of Cyp33, showing the requirement of PPIase activity for the
transcriptional repression of target genes 29.

JARID1 Histone Demethylases and their Functions
Until the first H3K4 demethylase LSD1 was identified in 2004, the main
mechanism to erase methyl marks was thought to be through passive dilution through
successive cell division. LSD1 is a dual specificity demethylase that demethylates
H3K4Me1 and H3K4Me2 and H3K9me1 and H3K9me2 90,91. In 2006 and 2007, a series
of reports discovered the JARID1 (KDM5) family of mammalian demethylase that
demethylates mono-, di-, and tri-methyl histone H3-K4. The JARID1 family also known
as the KDM5 (Lysine demethylase5) family comprises of JARID1A, JARID1B,
JARID1C and JARID1D. Like MLL, these proteins are also conserved throughout
metazoan. The Drosophila homologue of JARID1 is called Lid (Little Imaginal Disc) 92.
All JARID1 family members have JmjN, ARID domain (AT Rich DNA Interacting
Domain), PHD, zinc finger domains and a catalytically active JmjC domain that has the
demethylase activity.
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Figure 5: JARID1 family histone demethylases.

JARID1 family members, the histone demethylases remove trimethyl (Me3) mark
from histone H3K4. The Jumonji-C (JmjC) domain contains the demethylase
activity; the ARID domain is required for DNA binding. The PHD3 of JARID1A and
JARID1B bind to H3K4Me3. Thus JARID1A and JARID1B are erasers with
embedded readers for H3K4Me3 and are different from other two family members
JARID1C and JARID1D that lack a PHD3.
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The JmjN domain, ARID domains and zinc finger domains are all required for the
demethylase activity of JmjC domain. The ARID domain binds to AT rich DNA
sequences and thus imparts some specificity in binding to DNA. Of all the family
members, JARID1A and JARID1B have similar domain architecture and are partially
redundant in function 93. Both JARID1A and JARID1B are “erasers” with embedded
“readers”. There are three PHD fingers in JARID1A and B. JARID1C and JARID1D lack
PHD3. The 3rd PHD finger of JARID1A and JARID1B act as a ligand for H3K4Me3.
The 2nd PHD finger of JARID1C specifically binds H3K9Me3 35. JARID1A is
ubiquitously expressed, whereas JARID1B is expressed at low levels ubiquitously, except
for the testis where there is higher level of expression. JAR1D1C and JARID1D are
encoded by genes on the X and the Y chromosomes respectively. JARID1B was
identified as an oncogene that is frequently over expressed in breast cancer. There is
mounting evidence showing that JARID1B is over expressed in other human cancers like
prostate, bladder, renal, and lung cancers, AML and CML. Though JARID1A and
JARID1B are implicated as oncogenes, JARID1C and D are considered as potential
tumor suppressors. There are inactivating mutations in JARID1C in kidney cancer and
JARID1D is deleted in prostate cancers 86.

PHD Fingers of Other Chromatin-Associated Proteins
The PHD finger was first identified in the homeo domain containing protein HAT
3.1 in Arabidopsis and hence named as Plant Homeo Domain 94. PHD fingers are about
60- 65 amino acids in length typically. However some atypical PHD fingers are about 80
amino acids long. More than 200 proteins in the nucleus contain PHD finger and a
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majority of them are transcription regulators and chromatin associated proteins 95. They
have conserved regularly spaced cysteines, similar to that of the zinc fingers present in
many transcription factors. Cys4–His-Cys3 is the amino acid sequence in a PHD finger
that is required to co-ordinate two zinc atoms. Some atypical PHD fingers like that of
RAG2 have Cys3-His2-Cys3 architecture to co-ordinate the zinc atoms 96. Besides its
role in DNA binding and mediator of protein–protein interactions, the biological function
of PHD fingers have remained elusive since its discovery in 1993. The research over the
past decade has highlighted the PHD fingers as readers or binding modules for modified
and unmodified histones. In 2006, at least 6 different groups reported that the conserved
aromatic residues present in PHD fingers of BPTF, NURF, ING2 and Yng1 forms an
aromatic cage which serves as a binding pocket for trimethylated histone H3K4 35,97,98.
Now there are about 15 different chromatin associated proteins that have PHD fingers
that recognize H3K4Me3 (Table1) 35.
In addition to binding to methylated H3K4, the PHD fingers are now known to
bind unmethylated H3K4, H3K36me3, H3K9Me3, H3K14 ac and H3R2 35 . PHD fingers
of BPTF, RAG2 and BHC30 recognize multiple but specific histone modifications. This
combinatorial modification recognition by a PHD finger is plausible because the ligands
(histones) may bind to different regions in the PHD finger and may influence one
another’s binding positively 98. Also, multiple modifications are recognized by the same
protein; for example, the bromo-domain of BPTF binds acetylated lysines and the PHD
finger binds to H3K4Me3. In many of the chromatin associated proteins there are more
than one PHD finger. The importance of the adjacent PHD fingers present in a same
protein in recognizing the cognate histones is not yet well characterized. DPF3b PHD
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fingers are the only known example wherein the PHD finger1 and 2 of DPF come
together and form a binding pocket to recognize H3K14ac (Zeng et al. 2010) 99.
The PHD fingers are present in writer proteins that post translationally modify
histones, eraser proteins that remove the histone modifications or may be present in a
chromatin associated protein that recruits other transcriptional effector proteins. Hence
the functional outcome of the PHD finger recognizing its cognate histone depends on the
protein the PHD finger is present.

Mutations of PHD Fingers
Point mutations in the PHD finger region (N216S, V218I, and G221V) of ING
family tumor suppressors are found in human cancers. These mutations result in about
10-40 fold decrease in the PHD finger binding to H3K4Me3 (Baker et al. 2009). Point
mutations in the PHD finger region of RAG2 which affect the H3K4Me3 binding leads to
decreased catalytic activity of the recombinase enzyme which is important for V(D)J
rearrangement required for the development of B/T cells. An immunologic disorder,
Omenn syndrome is a classic example where in the mutations in the PHD finger of
RAG2 affect the H3K4Me3 binding are common. Especially there is higher incidence of
W453R mutation in patients with Omenn’s syndrome. This mutation specifically occurs
in one of the three amino acids that contribute to the aromatic cage formation that
disrupts the RAG2 PHD and H3K4Me3 interaction 100. PHD fingers that bind H3K4Me3
can become a part of another protein by chromosomal translocations. Thus the fusion
protein will have the acquired ability to bind H3K4Me3. The NUP98-JARID1A fusion
occurs in rare cases of AML. NUP98 is a nucleoporin that shuttles between the nuclear
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pore complex and regions of active transcription. The PHD finger 3 of the JARID1A
histone demethylase or PHF23 that binds to H3K4Me3 can fuse to NUP98 resulting in a
fusion protein. Both JARID1A and PHF23 PHD fingers can bind to H3K4Me3
explaining a common mechanism for leukemogenesis 101.
Table 1: PHD fingers of Chromatin-Associated Proteins that Bind H3K4Me3
Protein

Host Complex

Function of the complex
(function of the protein)

BPTF

NURF

ATP-dependent chromatin remodeler

ING1
ING2
ING3
ING4

mSin3a/HDAC1
mSin3a/HDAC1
NuA4/Tip60
HBO1
MOZ/MORF
HBO1

Histone deacetylase
Histone deacetylase
Histone acetyltransferase
Histone acetyltransferase
Histone acetyltransferase

ING5

Biological Outcome
Nucleosome mobility
Transcription activation
Transcription repression
Transcription repression
Transcription activation
Transcription activation
Transcription activation

JARID1A (KDM5A)
KDM7A
KIAA1718
MLL1
COMPASS-like

(Histone demethylase)
(Histone demethylase)
(Histone demethylase)
(Histone methyltransferase)
Histone methyltransferase

Transcription repression
Transcription activation

PHF2
PHF8
PHO23
PYGO1/2

Rpd3
PYGO1/2/BCL9

(Histone demethylase)
(Histone demethylase)
Histone deacetylase
Transcription factor
Wnt signaling

Transcription activation
Transcription activation
Transcription repression

RAG2
TAF3
YNG1
YNG2

RAG1/2 V(D)J
TFIID
NuA3
NuA4

Recombinase
Transcription factor
Histone acetyltransferase
Histone acetyltransferase

Recombination
Transcription activation
Transcription activation
Transcription activation

Transcription activation

Transcription activation

CHAPTER 3
MATERIALS AND METHODS
Cloning Techniques Used In This Study
Restriction Enzyme Digestion and Inactivation: Restriction endonuclease digestion of
plasmid DNA was performed using the Fast Digest enzymes from Fermentas. 1-2µg of
plasmid DNA was digested with 1U of the enzyme and 1µl of 10X Fast Digest buffer in a
10µl reaction for 10-15 minutes at 37°C. The enzyme was heat activated for 10 minutes;
the temperature varies from 65-80°C, depending on the enzyme used.
Dephosphorylation of the vector: If the ends of the restriction digested vector DNA
were compatible, the vector can re-ligate and form colonies upon transformation. To
avoid this, after restriction digestion the vector fragment was dephosphorylated using 1µl
of Fast Alkaline Phosphatase from Fermentas at 37°C for 10 minutes. The enzyme was
heat inactivated at 80°C for 10 minutes.
Isolation of DNA restriction fragments from agarose gels: The digested DNA and an
appropriate molecular weight marker were separated in 1% agarose gels in 1x TAE
buffer (400mM Tris-acetate, 1mM EDTA). The gel was stained in ethidium bromide and
destained in de-ionized water. The bands were visualized under UV and the DNA
fragment of interest was identified based on the expected molecular weight. The DNA
fragment of interest was excised from the gel. DNA was extracted from the gel slice
using the Promega PCR clean up kit.
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The extracted vector and insert DNA fragments were quantified by running on 1%
agarose gel containing ethidium bromide and compared to the bands of known
concentration and weight using a marker.
Ligation: The ligation was performed using T4DNA ligase from Fermentas. The gel
purified vector and insert DNA fragments were mixed in 3:1 molar ratios in a 10µl
reaction containing 1U of T4 DNA ligase from Fermentas and 1µl of 10X Ligase buffer
containing ATP. Thermoligations were performed in a PCR machine overnight.
Transformation: 2µl of ligation reaction was electroporated into DH10B bacteria using
a cell porator from GIBCO BRL according to the manufacturer’s protocol. 500µl of LB
media was added to the electroporated bacteria and incubated at 37°C with shaking at 225
rpm for 1 hour and then 100µl of the bacteria were plated on a LB ampicillin (100µg/ml)
plate and incubated for 16-18 hours at 37°C.
Identification of the bacterial clone containing the ligated vector and insert plasmid:
Individual colonies were picked and grown in 5ml of LB broth containing 100µg of
ampicilin (or appropriate selection antibiotic resistance conferred by the plasmid). For
larger constructs 50µg of ampicilin was used. The cultures were grown over night at
37°C in a shaking incubator at 225 rpm. The plasmid DNA was extracted from the
bacteria using the Promega Plasmid Purification kit (mini preps). The plasmids
containing the inserts in right orientation were identified by restriction digestion. To
obtain larger quantity of DNA, Maxi prep was performed using Qiagen Maxi Prep
Plasmid DNA purification kit.
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Table 2. Expression Plasmids used in this study
Plasmid

Vector
size
(Kb)
10.2
10.2

Insert
size
(Kb)
----3.0

Flanking
Restriction sites

pCep4 FLAG PPiase
mutant

10.2

3.0

KpnI…XhoI

pCXN2 FLAG MLL-N

5.2

6.5

EcoRI…XhoI

Full length
(R191A,
F196A)
1-2158

pcI FLAG MLL-N

5.7

6.5

XhoI

1 to 2665

pGEX4t1 GST MLL
PHD2
pGEX4t1 GST MLL
PHD3
pGEX4t1 GST MLL
PHD3 M1585A
pGEX4t1 GST MLL
PHD3 M1606D
pGEX4t1 GST MLL4
PHD3 (ALL2)
MSCV neo
MSCV neo MLL-N
wild type
MSCV neo MLL-N
M1585A
MSCV neo MLL-N
M1606D
MSCV puro
MSCV puro FLAG
MLL-ENL

4.9

0.2

BamHI…XhoI

1480 to 1540

4.9

0.32

EcoRI…XhoI

1531 to 1635

4.9

0.32

EcoRI…XhoI

4.9

0.32

EcoRI…XhoI

4.9

0.32

EcoRI…XhoI

1531 to 1635
M1585A
1531 to 1635
M1606D
1335 to 1396

6.4
6.4

----8.0

-------XhoI

-------1 to 2665

6.4

8.0

XhoI

1 to 2665

Clontech
Wei Wei
Diaz lab
This study

6.4

8.0

XhoI

1 to 2665

This study

6.3
6.3

----4.8

------EcoRI…XhoI

Clontech
Wei Wei
Diaz lab

MSCV puro FLAG
MLL-AF9
pCMV Myc
MLL C
Shcontrol pSIRENRetroQ
Sh JARID1b pSIRENRetroQ

6.3

4.35

EcoRI…BglII

3.8

3.75

XhoI

-------MLL 1-1394
ENL 372560
MLL 1-1362
AF9 481-568
2720-3969

6.4

BamH1…EcoRI

--------

6.4

BamH1…EcoRI

--------

pCep4
pCep4 FLAG Cyp33

------KpnI…XhoI

Protein
length/
Amino acids
-------Full length

Source or
Cloned by
Invitrogen
Ute
Osmers
Ute
Osmers
James
Hsieh
James
Hsieh
This study
Ute
Osmers
This study
This study
This study

Wei Wei
Diaz Lab
James
Hsieh
Ralf
Janknecht
Ralf
Janknecht
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Generation of MSCV neo MLL-N M1585A and M1606D
Step 1: Generation of MLL PHD3 mutants in pGEMT EZ
pCXN2 FLAG tagged MLL-N was kindly provided by Dr. James Hsieh from
Memorial Sloan Kettering. A 2.3kb fragment of MLL-N which comprises the CXXC
domain and PHD fingers was digested with AatII and NdeI and ligated into AatII and
NdeI sites of pGEMT EZ (Promega). 20ng of this plasmid DNA was subjected to PCR
based site directed mutagenesis using a forward primer containing the mutation and a
reverse primer which anneals 200 bp downstream of the forward primer. The PCR
products were digested with DpnI to get rid of the remaining input plasmid DNA and
then transformed into DH10B bacteria. The transformants harboring the mutations were
verified by DNA sequencing.
Table 3. Primers Used for Site Directed Mutagenesis
Primer Name
MLL PHD3
M1585A F
MLL PHD3
M1606D F
MLL PHD3 R

Sequence 5`-3`
GACTATGAGAGTAAGGCGATGCAATGTGGAAAG
GAGAATCTTTCAGATGAGGACTATGAGATTCTATCTAATC
GGAAGGTATACTCTCCTCTGTCTC

Step 2: Cloning of the full length MLL-N wild type and mutants in pBK(-)
Wei Wei in our lab cloned the 8.0kb wild type MLL-N into XhoI site of pBK (-)
(Stratagene) from pcI MLL-N provided by Dr. Hsieh. The PHD3 mutants in pGEMT EZ
were digested with AatII and NdeI, these 2.3kb fragments were swapped in for the wild
type AatII …NdeI fragment in pBK(-) full length MLL-N.
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Step 3: Cloning of MLL-N wild type and the mutants into MSCV neo
The 8.0kb MLL-N wild type or the mutants in pBK were digested with XhoI and
ligated into the XhoI site of MSCV neo. The orientation of the insert was verified by
restriction digestion and further confirmed by DNA sequencing.

Cell culture
The human cell line used in this study is HEK 293T. HEK 293T cells were grown
in DMEM containing 10% FBS and 1% penicillin-streptomycin. The cells were
maintained in culture by trypsinizing and splitting every 2 days. The mouse cell line used
in this study is Mouse Embryonic Fibroblast (MEF). They are wt for MLL and grown in
DMEM containing 10% FBS and 1% penicillin-streptomycin B-mercaptoethanol. Cells
were trypsinized and re-plated every 2 days.
Transfection
HEK 293T cells were transfected using Lipofectamine-2000 (Invitrogen). Cells
were trypsinized and plated in a 10cm dish at least 4 hours prior to transfection. The cells
were approximately 40% confluent at the time of transfection. 15-20µg of plasmid DNA
was transfected with 30µl of lipofectamine according to the manufacturer’s protocol.
DNA-lipofectamine complex was allowed to form at room temperature for 20 minutes in
serum free media. The transfection mixture was added to the cells. The media was
changed after 12 hours and the cells were harvested after 48 hours after transfection for
experiments. If the transfected plasmids encode for drug resistance, then transfectants
were selected using the specific drug (puromycin 1µg/ml for HEK 293T cells).
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Retroviral packaging and concentration
3x106 ecotropic Phoenix virus packaging cells (Garry Nolan / Orbigen) were
plated in a 10cm dish; five plates were plated per sample. The following day, 25µg of
retro viral plasmid DNA per 10cm dish was transfected using calcium phosphate; to
enhance the viral production 2.5µg of viral packaging plasmid was co-transfected. 14-16
hours post transfection 7ml of fresh DMEM containing 10% FBS and 1% Pen/Strep was
added to each plate and the cells were incubated at 32°C with 5% CO2. The Phoenix eco
cells are adherent cells; the retroviral plasmid transfected cells release the viruses into the
media. Hence the media containing the viruses were collected from the transfected cells
and stored at 4°C. Fresh media was added to the cells, the cells were incubated at 32°C
with 5% CO2 to make more viruses. After 24 hours the media was collected again and
combined with the media already collected, then spun down to remove any cell debris.
The solution containing the retroviruses were concentrated about 7 times using Centricon
Plus 70 filters (Millipore) by centrifugation in a swing bucket JS 7.5 rotor. Concentrated
retroviruses were aliquoted, snap frozen, and stored at -80°C. The plasmids used for
retroviruses were MSCV neo, MSCV neo MLL-N wt, MSCV neo M1585A, MSCV neo
M1606D, and MSCV puro MLL-AF9 (Table 2).

Titration of Retrovirus
8.5x104 Rat 1a cells were plated in 6 well plates in DMEM containing 10% FBS
and 1% Pen/Strep. The following day, Rat1a cells were infected with serial dilutions of
the virus from 1x103 to 1x106 with 16µg/ml of polybrene in 1ml of DMEM containing
10% FBS. After 2 hours, the media containing polybrene was removed from the plates
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and replaced with DMEM and 10% FBS. 24hours post-infection, the media was removed
and fresh media containing 1mg/ml of G418 was added to select for the cells that have
been transduced with the viruses. After the no virus control cells died (about 10 days), the
colonies formed by virus infected cells were washed with PBS and stained with 1ml of a
solution of 0.1gm methylene blue in 60 ml Methanol for 5 minutes. Plates were rinsed,
dried, and then colonies were counted to determine the virus titer.

Retroviral Transduction of MEFs
About 0.5x106 were plated on 6 well plates. After 3-4 hours the old media was
removed and replaced with 1ml of media (DMEM 10% FBS, 1% Pen Strep) containing
750µl of concentrated retro virus, 4µg/ml of polybrene, 1 M HEPES was added. The
plates were incubated at 32°C with 5% CO2 for 4 hours. Then the media containing the
virus was removed and replaced with fresh MEF media. Since the plasmid packaged into
the virus encodes for neomycin resistance, the transductants were selected using G418
1mg/ml.
Isolation of Cells from Mouse Bone Marrow
One C57Bl/6 mouse, age 8-12 weeks, was sacrificed by CO2 inhalation. Tibias
and femurs were collected in a cell culture dish with RPMI 2% FCS. Excess tissue was
removed from bones with sterile gauze. 8ml RPMI 2% FCS was added to a 10cm plate.
Using a 25 gauge 1.5” needle and media in the dish, bone marrow was flushed into the
plate until bones appear white. Cells were separated from the rest of the tissue debri by
passing through a mesh. Cells were spun down at 1500 rpm for 5 minutes at 4°C, then
resuspended in 5ml 1X cold sterile red cell lysis buffer (10X RBC lysis buffer: 83gm
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NH4Cl, 10gm NaHCO3, 0.37gm EDTA in 1l H20) and incubated on ice for 5 minutes.
Cells were spun down at 1500 rpm for 5 minutes at 4°C, then resuspended in 10 ml PBS
2% FCS to create a single cell suspension and then proceeded with C-Kit positive
selection to enrich for the hematopoietic progenitors population.

C-Kit Positive Selection of Mouse Bone Marrow Cells
To select for the C-Kit+ hematopoietic progenitor cells in the mouse bone
marrow, I followed the Easy Sep Mouse CD117 (c-Kit) Positive Selection Kit (#18757
Stem Cell). Cells were resuspended at 100x106 cells per ml in PBS 2% FBS, in a Falcon
5ml Polystyrene Round-Bottom Tube. CD117 antibody (with Fc blocker) was added to
cells at 70μl/ml cells. Solution was mixed and incubated at room temperature for 15
minutes. Easy Sep PE selection cocktail was added at 70μl/ml cells. Solution was mixed
and incubated at room temperature for 15 minutes. Magnetic nanoparticles were mixed
by pipetting 5 times, and then added to the cell solution at 50μl/ml cells. Solution was
mixed and incubated at room temperature for 10 minutes. Cell suspension was next
brought up to 2.5mL with PBS 2% FBS. Cells were mixed by pipetting 2-3 times. Tube
without cap was placed in chilled Easy Sep magnet and allowed to sit for 5 minutes.
Without removing the tube from the magnet, the supernatant was carefully removed. The
tube was removed from magnet and 2.5 mL PBS 2% FBS was added to cells, pipetting 23 times to mix. Magnet separation was repeated for a total of four 5 minutes separations.
Cells were resuspended in 1.5mL PBS 2% FBS and counted. Cells were plated overnight
in a round bottom 96 well dish at 1 million per 1mL of RPMI 1640 media with 10% FBS
(heat inactivated at 55°C for 1hour) , 1% Pen-Strep, and supplemented with100ng/ml
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SCF, 10ng/ml IL3, 10ng/ml IL6, 10ng/GM-CSF. Sterile H20 was added to wells
surrounding the cells to keep them from drying out.

Retroviral Transduction of C-Kit+ Hematopoietic Progenitors
The day after C-Kit positive selection, 200,000 cells C-Kit positive hematopoietic
progenitors, 1.5ml of concentrated retro virus, 15.0μl 1M HEPES, 8μg of polybrene
(Sigma) were mixed and the volume was made up to 2ml with RPMI 1640 media
containing 10% FBS. Further, spinoculated at 3000 rpm in Beckman GS6KR centrifuge
at 32°C for 4 hours. After spinoculation, without disturbing the cell pellet, the
supernatant containing the polybrene and virus was carefully removed. The cells were
then resuspended in RPMI 1640 media with 10% FBS (heat inactivated at 55°C for
1hour) , 1% Pen-Strep, and supplemented 100ng/ml SCF, 10ng/ml IL3, 10ng/ml IL6,
10ng/GM-CSF; and plated in 96 well plate. To ensure an efficient transduction of
hematopoietic progenitors, a second spinoculation was performed the following day and
cells were resuspeded in RPMI 1640 media with 10% FBS (heat inactivated at 55°C for
1hour) , 1% Pen-Strep, and supplemented 100ng/ml SCF, 10ng/ml IL3, 10ng/ml IL6,
10ng/GM-CSF and plated in 96 well plate.

Liquid Culture of Transduced Hematopoietic Progenitors
The day after retroviral transduction of hematopoietic progenitors, a portion of the
cells ( about 70,000 rest 30,000 was used for colony assay) were selected with G418
1mg/ml (MSCV neo) or puromycin (MSCV puro) 1μg/ml depending on the resistance
marker encoded by the plasmid DNA used for retro virus production and cultured in
RPMI 1640 media containing 10% FBS (heat inactivated at 55°C for 1hour), 1% Pen-
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Strep, 100ng/ml SCF, 10ng/ml IL3, 10ng/ml IL6, 10ng/ml GM-CSF. Every 2 -3 days
depending on their growth rate the media was removed and replaced with fresh media
containing the indicated cytokines and selection drugs. After 4 days of selection cells
transduced with MSCV neo, MLL-N wt, M1585A, or M1606D were harvested for RNA
extraction.

Hematopoietic Progenitors Colony Formation Assay
The day after retroviral transduction of hematopoietic progenitors, 30,000 cells
were added to 3ml of methyl cellulose supplemented with 100ng/ml SCF, 10ng/ml IL3,
10ng/ml IL6 ( Stem cell technologies). Additionally, 10ng/ml GM-CSF and the selection
drug G418 (1mg/ml) or puromycin (1μg/ml) was added and mixed very well by
vortexing. About 1ml of the mixture was plated on to 35mm petri-dish. The platings were
performed in duplicates. About 10,000 cells were plated in each plate for MSCV neo,
MLL-N wt, M1585A or M1606D; about 1,000 cells were plated in each plate for MLLAF9 transduced cells. The plates were placed in humid chamber and incubated at 37°C
with 5% CO2 and left undisturbed for a week. The hematopoietic progenitors should
proliferate and form colonies on methyl cellulose. After a week, the number of colonies
in each dish was counted. The transformation of hematopoietic progenitor was assessed
by dissociating the colonies and re-plating the cells in methyl cellulose successively.

RNA Extraction, DNAseI treatment, cDNA synthesis and qRT-PCR
5x106 to10x106 cells were pelleted by centrifugation. The loosened cell pellets
were lysed in 1ml of TRIzolTM (Invitrogen). 200µl of chloroform was added to the
samples and mixed very well. The samples were incubated at room temperature for 2-3
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minutes and then centrifuged at 12000 rpm for 12 minutes at 4°C. The upper layer (the
aqueous phase) was carefully transferred to a fresh tube and the RNA was precipitated by
adding an equal volume of isopropyl alcohol followed by centrifugation at 12000 rpm for
10 minutes. The pellet was washed once with 75% ethanol prepared in diethyl
pyrocarbonate (DEPC) treated water. RNA pellet was air dried for 5-7 minutes and
dissolved in 50µl of DEPC treated water by incubating at 55°C for 5 minutes.
Concentration of the RNA at 260nm was measured using Nanodrop 2000c.
The RNA extracted by the above mentioned method may have some amount of
DNA which will confound the RT-PCR results. Hence, the RNA preparation has to be
subjected to DNAseI digestion. About 3µg of RNA was digested with DNAseI
(Fermentas) according to the manufacturer’s protocol. The DNAseI was inactivated by
adding 50mM EDTA at 65°C for 10 minutes. Each DNAseI treated RNA sample was
split into two halves. One half was used for cDNA synthesis with reverse transcriptase;
the other was used as a control for DNAseI treatment wherein cDNA synthesis was
performed without adding the reverse transcriptase (no RT control). cDNA will not be
made in no RT control , hence any amplification detected in this sample will be from the
remaining DNA present in the RNA sample. cDNA synthesis was performed using the
high capacity cDNA synthesis kit from Applied Biosystems according to the
manufacturer’s protocol. cDNA samples were diluted 1:5 in nuclease free water and
qRT-PCR was performed with GoTaq Sybr green from Promega. PCR for a specific
primer set was performed in triplicates for each cDNA sample in a 96 well plate in ABI
3700 real time PCR machine. Sybr green is a fluorescent dye that intercalates DNA, and
fluorescent signal at every cycle is recorded. Cycle threshold (Ct) value is the measure of
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the amplicon signals that are detected at the linear phase of amplification and are above
the background. Ct value is obtained by analyzing the raw data using the ABI PRISM
7300 software. The ct values (cycle threshold value) were obtained by performing the
analysis using ABI Prism 7300 software.
Table 4. Human qRT-PCR Primers
Primer Name
ACTB F
ACTB R
GAPDH F 261
GAPDH R 417
B2M F
B2M R
HPRT1 F
HPRT1 R
PGK1 F
PGK1 R
TBP F
TBP R
HOXA9 F
HOXA9 R
HOXC8 F
HOXC8 R
CDKN1B F
CDKN1B R
MEIS1 F
MEIS1 R
MYC F
MYC R
CYP33 F
CYP33 R
MLL F
MLL R
KDM5A F
KDM5A R
KDM5B F
KDM5B R

Sequence 5'-3'
CGTACCACTGGCATCGTGAT
GTGTTGGCGTACAGGTCTTTG
ATGGCAAATTCCATGGCACCGT
ATGGTGGTGAAGACGCCAGT
TGCTGTCTCCATGTTTGATGTATCT
TCTCTGCTCCCCACCTCTAAGT
TGACACTGGCAAAACAATGCA
GGTCCTTTTCACCAGCAAGCT
CTGTGGGGGTATTTGAATGG
CTTCCAGGAGCTCCAAACTG
TATAATCCCAAGCGGTTTGC
GCTGGAAAACCCAACTTCTG
TCCCACGCTTGACACTCACACTTT
AGTTGGCTGCTGGGTTATTGGGAT
TGGAAACCTGAAGGAGATGTGGGT
AAACAGGGAAGGAGAGGAAGGCAT
CCGGCTAACTCTGAGGACAC
CTTCTGAGGCCAGGCTTCTT
CAGAAAAAGCAGTTGGCACA
TCATGCCCATTCCACTCATA
CCTACCCTCTCAACGACAGC
CTCTGACCTTTTGCCAGGAG
TCCAGGCCAGTTTGGTCAGATGAT
CCGGCTTGTTCCCAATCTTGATGT
ATGTGGAAAGTGTGATCGCTGGGT
TGCCGCTCAGTACAGTTCACACAA
TGTCCTAAATGTGTCGCCGAGGAA
TGTGGGAACCATATGGACTGGCAT
AATTTGGCAGTGGCTTTCCTGTCC
CTGCTCCATCACTGGCATGTTGTT
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Table 5. Mouse qRT-PCR Primers
Primer Name
m Actb F
m Actb R
m Gapdh F
m Gapdh R
m Hoxa9 F
m Hoxa9 R
m Hoxc8 F
m Hoxc8 R
m Cdkn1b F
m Cdkn1b R
m Cdkn1a F
m Cdkn1a R
m Meis 1 F
m Meis 1 R
m Myc F
m Myc R
m Pu.1 F
m Pu.1 R

Sequence 5'-3'
GGCTGTATTCCCCTCCATCG
CCAGTTGGTAACAATGCCATGT
GTGAACGAGAAGGACTATAACCC
GGCTGTGTAGGAATGGACTG
TACTATGTGGACTCCTTCCTGC
TTCCACGACGCACCAAACAC
GACGCCTCCAAATTCTATGGC
AGACGAGTTCTGATTTAAGTGGCC
CGCCAGACGTAAACAGCTCCGAATTA
AGAGGCAGATGGTTTAAGAGTGCC
TGTCTGAGCGGCCTGAAGATT
AGACCAATCTGCGCTTGGAGTGAT
CTCCTCTGCACTCGCATCAG
CCATGGCGTTGGTATGAGCT
CCCACCACCAGCAGCGACTC
GCGGAGGTTTGTGGCCT
TGGAACAGATGCACGTCCTCGATA
TCCAAGCCATCAGCTTCTCCATCA

Fold change in gene expression was calculated by normalizing the average ct value of
gene of interest for a given sample to the ct value for a house keeping gene for the same
sample. Relative fold change in gene expression was calculated by setting the control to
one and comparing the change in expression of other samples with respect to the control.

Chromatin immunoprecipitation (ChIP) followed by quantitative PCR
10x106 cells in 10ml of media were cross linked with formaldehyde (1% final
concentration) for 15 minutes at room temperature. The cross linking was stopped by
adding 1ml of 1.25 M glycine. The cells were washed with cold PBS twice and pelleted
at 2000 rpm. To the cell pellet 500µl cell-lysis buffer (3mM MgCl2, 10mM NaCl, 10mM
Tris (pH 7.4) and 0.1% NP40) containing protease inhibitor (cocktail from Roche) was
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added and incubated on ice for 15 minutes with intermitten vortexing every 5 minutes.
The samples were centrifuged for 5 minutes at 2000 rpm at 4°C. The supernatant was
removed and to the pellet 500µl of nuclear lysis buffer (1% SDS, 10mM EDTA, 50mM
Tris (pH 8.0)) containing protease inhibitor was added and sonicated on ice to shear the
DNA to an average length between 200 bp to 1000 bp. The sonication was performed
using a Cole Parmer, High Intensity Ultrasonic Processor/Sonicator, 50 watt model with a
2mm tip set to a power of 4 or 5. 293T cells were sonicated at setting 4, 6 pulses, 5 times.
MEFs were sonicated at setting 5. The samples were centrifuged for 10 minutes at 13,000
rpm at 4°C. The debri was removed. The supernatant (nuclear lysate) was used for the
immunoprecipitations. 50µl of the nuclear lysate was diluted 10 times with ChIP dilution
buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl (pH 8.0),
167 mM NaCl) containing protease inhibitor, to which indicated amount of primary
antibody (Table 6) and 20µl of Protein-A magnetic beads (Millipore) were added and
mixed very well and immunoprecipitations were performed on an overhead turner
overnight at 4°C. 10µl of nuclear lysate from each sample was kept aside as input to
normalize for the amount of DNA present in each sample. The magnetic beads were
allowed to attach to the walls of the tube using a magnetic rack (Millipore) for 30
seconds. The supernatant was discarded. The magnetic beads protein A/ antibody/
chromatin complexes were washed in 500µl the following buffers for 3-5 minutes with
rotation at 4°C. Low Salt Wash Buffer: (0.1% SDS, 1% Triton X-100, 2mM EDTA,
20mM Tris-HCl (pH 8.0), 150mM NaCl), High salt wash buffer: (0.1% SDS, 1% Triton
X-100, 2mM EDTA, 20mM Tris-HCl (pH 8.0), 500mM NaCl), LiCl Wash buffer:
(0.25M LiCl, 1% IGEPAL-CA630 or NP40, 1% Deoxycholic acid (sodium salt), 1mM
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EDTA, 10 mM Tris (pH 8.0)) and TE Buffer: (10mM Tris-HCl (pH 8.0), 1mM EDTA).
Bound DNA was eluted from the magnetic beads using 100µl elution buffer (0.1M
NaHCO3, 1% SDS) and1µl of Proteinase-K 10mg/ml, mixed very well and incubated at
62°C for 2 hours with rotation. The Proteinase-K was inactivated at 95°C for 10 minutes.
The protein-free DNA was eluted from the magnetic beads. The DNA was recovered and
purified using Mol Bio PCR clean up kit according to the manufacturer’s protocol.
Similar to the IP samples the inputs were also processed for elution and Proteinase-K
digestion and purification of DNA. The eluted DNA was diluted 5 times in nuclease free
water and qPCR was performed in triplicates for each sample in a 96 well plate in ABI
3700 real time PCR machine with the primers specific for the gene of interest (Table 7
and Table 8) using the GoTaq Sybr green from Promega. The fold recruitment of a
specific chromatin associated protein was calculated by normalizing the amount of
chromatin immunoprecipitated DNA to the amount of input DNA, and subtracting from
the background (IgG pull down) levels. The fold enrichment for the histone modifications
was calculated by normalizing first to the input levels and then to the amount of histone
H3 levels present at the region of interest.
Table 6. Antibodies Used in ChIP
Antibody
Anti histone H3
Anti histone H3K4Me3
Anti acetyl histone H3
Anti acetyl histone H3K27
Anti JARID1A
Anti JARID1B
Rabbit IgG (negative control)
Mouse IgG (negative control)

Manufacturer/Catalogue
#
Millipore 05-499
Abcam ab1791
Millipore 17-614
Millipore 06-599
Millipore 07-360
Abcam ab70892
Abcam ab50958
Millipore 12-370
Millipore 12-371B

Amount used/ ChIP
5µl
3µl
5µl
5µl
7.5µl
7.5µl
5.0µl
5.0µl
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Table 7. Human ChIP Primers
Primer Name
ACTB Promoter F
ACTB Promoter R
GAPDH Promoter F
GAPDH Promoter R
B2M Promoter F
B2M Promoter R
BGLOBIN Promoter F
BGLOBIN Promoter R
Histone H4 Promoter F
Histone H4 Promoter R
RPL10 Promoter F
RPL10 Promoter R
HOXA9 Promoter F
HOXA9 Promoter R
HOXC8 Promoter F
HOXC8 Promoter R
CDKN1B (p27) F
CDKN1B (p27) R
JARID1B Promoter F
JARID1B Promoter R
HDAC1 Promoter F
HDAC1 Promoter R

Sequence 5'-3'
TGCACTGTGCGGCGAAGC
TCGAGCCATAAAAGGCAA
TACTAGCGGTTTTACGGGCGCACGT
TCGAACAGGAGGAGCAGAGAGCGA
AGACTTCCCAAATTTTGCCATCCTA
AAAGGCCTGAAATGTTAGTGTTGAGT
AGGGAGGGCTGAGGGTTTGA
CAGGGTGAGGTCTAAGTGATGACA
AAATGGTGGGATCACAGACG
CGAGCTTCTTGTTTCCGTGT
ACCCGTCTTCGACAGGACT
GGAACGGAAGACGAGGAGAACAG
GCCAACCAAACACAACAGTC
CAAATCGCATTGTCGCTCTA
GGCGAGAGGCACCTTCACATCTAAATTC
AGAGAGAGAGAGAGAGAGAGAGAGAGATGGC
CCGGCTAACTCTGAGGACAC
ATACGCCGAAAAGCAAGCTA
ACTTCTTCAGGGCAGGAACTCTGA
TCCGCTGTCGATGGAGTTTATCCT
CGGCTATAGGTGAGCCCAGGA
AACAGACTTTCCTCCGGGT

Table 8. Mouse ChIP Primers
Primer Name
m Actb Promoter F
m Actb Promoter R
m Gapdh Promoter F
m Gapdh Promoter R
m Hoxa9 Ch pro can F
m Hoxa9 Ch pro can R
m Hoxc8Promoter F
m Hoxc8 Promoter R
m Cdkn1b Promoter F
m Cdkn1b Promoter R

Sequence 5'-3'
AGCAATAGCCGGAAAGCCAGATCC
ACCACTGGGGCTCGCCCTATG
AGAGAGGGAGGAGGGGAAATG
AACAGGGAGGAGCAGAGAGCAC
CACTGCCTGAGACCACAGAA
AGGGAGCCTGGAGTACTGGT
AACCTGAGTTGACCTGATGGCTCA
CTAACTAATGGACAAGGCCAGCTT
CGGCCGTTTGGCTAGTTTGTTTGT
GGAGGCTGACGAAGAAGAAGATGA
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Western Blot and Immunoprecipitation
Cells were washed in PBS and pelleted down by centrifugation. Further, cell lysis
was performed using IPH lysis buffer (50mM Tris-HCl (pH 8.0), 150mM NaCl, and
5mM EDTA, 0.5% NP-40, 1X protease inhibitor (Roche) for 30 minutes on ice. The
cellular debri were removed by centrifugation at 12000 rpm 10 minutes at 4°C. Protein
concentration was estimated using BCA (Pierce) method. Depending on the abundance of
the protein in the cell, anywhere from 500 to 1500µg of protein was made up to 1ml with
1X IPH lysis buffer. To reduce non-specific binding, the lysate was pre-cleared with
ProteinA/G beads (Roche), depending on the isotype of primary antibody used for 1hour
at 4°C. The pre-cleared lysate was used for immunoprecipitation with the primary
antibody (at the concentration recommended by the manufacturer) along with ProteinA/G
beads (Roche) over night at 4°C. The immunoprecipitated protein complexes were
washed with lysis buffer for 4-5 times with 5 minutes intervals between each wash. After
the final wash, 2X loading dye (4% SDS, 10% 2-mercaptoethanol, 20% glycerol,
0.004% bromophenol blue, 0.125 M Tris-HCl) was added to the beads and denatured at
100°C and loaded onto SDS-PAGE (percentage of PAGE was ascertained based on the
molecular weight of the protein to be immune blotted) and the protein was
electrophorectically separated using the 1X Tris-Glycine running buffer (25 mM Tris
base, 190 mM glycine, 0.1% SDS pH 8.0). The separated proteins were
electrophoretically transferred to a PVDF membrane with a pore size of 0.45µM ( Pierce)
using 1X pre-chilled transfer buffer (25 mM Tris base,190 mM glycine, 20% methanol)
100 volts for 1 hour. After the protein was transferred to the membrane, to minimize the
non-specific binding of the antibody, the membrane was blocked in 5% non-fat skim milk
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in 1X TBS (24.23 g Tris-HCl, 80.06 g NaCl made up to 1L with water, pH to 7.6) for 1
hour at room temperature. Then, primary antibody was diluted as per the dilutions in the
table in 2.5% milk and added to the blot and left in the shaker over night at 4°C. The
following day the blot was washed in TBST (0.5ml of Tween 20 added to 1L of TBS), 10
minutes, three times. Depending on the organism in which the primary antibody was
raised, the corresponding secondary antibody (anti Rabbit or anti Mouse from Santa
Cruz) was added for 1hour at room temperature. To get rid of the unbound antibody, and
other non-specific binding the blot was washed three times with TBST and the blot was
developed with Enhanced Chemiluminescence kit (ECL Super signal, Dura) from
Pierce).

Table 9. Primary Antibodies Used in Western Blot
Antibody
Anti H3K4Me3
Anti MLL-N
Anti MLL-N
Anti MLL-C
Anti PPIE
Anti JARID1A
Anti JARID1B
Anti-FLAG M2
Anti HA

Manufacturer/Catalogue
#
Abcam 12209
Dr.Thirman
Bethyl lab
Dr.James Hsieh
Novus Biologicals
H00010450-A01
Abcam ab70892
Abcam ab50958
SIGMA F3165
Abcam 9110

Epitopes
recognized
1-100
1-371
1320-1380
2829-2883
2-101

Dilution

1675-1722
125-325
DYKDDDDK
YPAYDVPDYA

1:1000
1:1000
1:1000
1:1000

1:1000
1:1000
1:2500
1: 10000
1:1000

Western Blot for MLL-N
8x106 cells (MEF or 293T) were washed in PBS and centrifuged at 2000 rpm for
5 minutes. The pelleted cells were then lysed in 300µl of cell lysis (3mM MgCl2, 10mM
NaCl, 10mM Tris (pH 7.4) and 0.1% NP40) buffer for 15 minutes on ice with intermitted
vortexing followed by centrifugation at 3000 rpm for 5 minutes at 4°C. To the pellet,
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350µl of nuclear lysis buffer (1% SDS, 10mM EDTA, 50mM Tris (pH 8.0)) was added
and chilled in ice for few minutes and then sonicated on ice at setting 5 for 3 pulses two
times. The nuclear debri was removed by spinning at 12000 rpm for 10 minutes at 4°C.
The protein present in the nuclear extract was quantified by BCA (Pierce) method; 100µg
of the nuclear extract was mixed with 6X loading dye, denatured at 100°C for 5 minutes
and loaded on 3-8 % tris acetate gel from Invitrogen. The proteins were
electrophorectically separated using the 1X tris- acetate running buffer (Invitrogen) at
160 volts for 1hour and 30 minutes. The separated proteins were electrophoretically
transferred to a nitrocellulose membrane (High bond-C) with pore size 0.45µM
(Amersham) using 1X pre-chilled transfer buffer containing 10% methanol (Invitrogen)
at 100 volts for 3 hours. High molecular weight protein ladder from Fermantas was used
a guide for assessing the separation of proteins on the gel and for the efficient transfer of
protein to the nitrocellulose membrane. Following the transfer, blocking, primary
antibody, secondary antibody staining and developing the membrane with ECL was done
similar to the immune blotting for other proteins.

Nucleosome pull down assay
HEK 293T cells were transfected with 20µg of MSCV neo vector control; FLAG
tagged MLL-N wt, M1585A or M1696D with Lipofectamine-2000 (Invitrogen)
according to the manufacturer’s instruction. After 48 hours about 1 to 2x107 cells were
washed with PBS and resuspended in a ml of buffer A (10mM HEPES pH 7.9, 10mM
KCl, 1.5mM MgCl2, 0.34M Sucrose, 10% glycerol, 1mM DTT) containing protease
inhibitor cocktail (Roche). Triton X-100 was added to the final concentration of 0.1% and
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the resuspended cells were homogenized in a dounce homogenizer (about 8-10 strokes)
and then centrifuged at 4°C, for 5 minutes at 1300g. The nuclei in the pellet were washed
in 1ml of buffer A and then lysed in buffer B (3mM EDTA, 0.2mM EGTA,1mM DTT)
containing PI and the soluble and insoluble chromatin fraction was separated by
centrifugation at 4°C for 5 minutes at 1700g. The insoluble chromatin was resuspended
in 0.2ml of buffer M (10mM Tris pH 7.6, 10mM KCl, 1.5 mM CaCl2) prewarmed at
25°C. 1U of micrococcal nuclease (New England Biolabs) was added and the digestion
was performed for 5 minutes and 30 seconds. The reaction was stopped by adding 1mM
EGTA and then centrifuged at 4°C 1700g for 5 minutes. An aliquot of the supernatant
was de-proteinized using 1µl of 10mg/ml ProteinaseK at 62°C for 2 hours, followed by
heat inactivation of Proteinase K at 90°C for 10 minutes. DNA was purified by PCR
clean up kit and checked for predominant release of mononucleosomes in ethidium
bromide containing 1% agarose gel. The length of the DNA wound around a nucleosome
is approximately 146 bp. The remainder of the supernatant was adjusted to 0.5ml with
buffer C (15mM tris pH 7.6, 150mM NaCl, 1mM EDTA, 1mM DTT) containing PI and
incubated over night at 4°C with FLAG beads. The immunoprecipitaites were washed
with buffer C 4 times and eluted by boiling the beads in 2X SDS sample buffer for 5
minutes. Aliquots of input and immunoprecipitated eluates were subjected to immunoblot
analysis in a 15% SDS–PAGE and immunoblotted for H3K4Me3 (Abcam ab12209)
according to the manufacturer’s instructions 102.

CHAPTER 4
RESULTS
Aim1: Determine the effect of Cyp33 over expression on transcription of MLL
target genes.

Previous studies from our laboratory have shown that the MLL PHD3 interacts
with Cyp33 and over expression of Cyp33 results in transcriptional repression of MLL
target genes. These previous studies used semi-quantitative RT-PCR to measure the
effect of Cyp33 over expression on the transcription of MLL target genes 23,57. We have
confirmed those results using qRT-PCR, a more quantitative approach to measure gene
expression. The effect of Cyp33 over-expression on a panel of house-keeping genes was
tested by qRT-PCR (Figure 6A). Since the ct values of β2- microglobulin (B2M) mRNA
levels remain unchanged between vector-transfected control and Cyp33 over-expressing
cells, B2M is used as a reference gene. The effect of Cyp33 on the expression of MLL
target genes was measured by qRT-PCR (Figure 6B). Cyp33 over expression in 293T
cells resulted in a 2 fold decrease in expression of HOXA9, and 3.3 fold decrease in
expression of HOXC8 and CDKN1B (p27) all of which are known MLL target genes 11
Over-expression of Cyp33 was verified using qRT-PCR for CYP33 (Figure 6C ).
Nucleosome density and certain histone modifications are correlates of
transcription. To understand the mechanism of Cyp33 mediated transcriptional repression
of MLL target genes, ChIP for H3 and histone marks at the promoters of MLL target
53
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Figure 6: Effect of Cyp33 over expression on transcription of MLL target genes
A. qRT-PCR for House-Keeping genes

B. qRT-PCR for MLL target genes

p = 0.0268

p = 0.0141

C. qRT-PCR for CYP33

p = 0.0255

293T cells were transiently transfected with pCep4 (vector) or pCep4-Cyp33 plasmids
and harvested after 48 hours for RNA extraction, followed by qRT-PCR: A, for housekeeping genes; B, for MLL target genes; C, for Cyp33. n=3, average of three
independent experiments, error bars represent S.D. p values are from one- sample t- test.
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Figure 7: Effect of Cyp33 over expression on histone H3 density at MLL
target gene promoters
ChIP for H3 at MLL target gene promoter

p = 0.0061

p = 0.0146

p = 0.0439

293T cells were transiently transfected with pCep4 (vector) or pCep4-Cyp33
plasmids and harvested after 48 hours for ChIP for histone H3; Rabbit or mouse
IgG was used as a negative control for the pull-down. n=3, average of 3
independent experiments and error bar represents S.D. p values are from one
sample t- test.
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Figure 8: Effect of Cyp33 over expression on histone modifications at MLL target
gene promoters
A. ChIP for H3Ac at MLL target gene promoters

Relative Fold Enrichment

p = 0.0439

p = 0.0141

p = 0.0041

1.2

0.8

Vector
Cyp33

0.4

0

HOXA9

HOXC8

CDKN1B
(p27)

B. ChIP for H3K4Me3 at MLL target gene promoters

p = 0.0177

p = 0.0033

p = 0.0008

293T cells were transiently transfected with pCep4 (vector) or pCep4-Cyp33
plasmids and harvested after 48 hours for ChIP for: A, H3Ac; B, H3K4Me3, at MLL
target genes. The fold enrichment of histone H3 modifications was calculated by
normalizing the amount of histone H3 modification to the amount of total histone H3
present at a given promoter. Rabbit or mouse IgG was used as a negative control for
the pull-down. n=3, average of 3 independent experiments and error bar represents
S.D. p values are from one sample t- test.
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genes was performed. Over-expression of Cyp33 resulted in a statistically significant
increase in histone H3 density at MLL target gene promoters which is consistent with the
reduction in MLL target gene expression (Figure 7).
Studies from our laboratory have shown that Cyp33 over expression did not affect
the histone marks like H3K27Me3 and H3K9Me3 associated with gene silencing. To test
whether marks that are associated with active transcription change with Cyp33 over
expression, a ChIP for transcription activation-associated histone marks like H3K4Me3
and H3Ac at the promoters of MLL target genes was performed. To determine the fold
enrichment of a particular histone modification at a given promoter, the amount of a
particular H3 modification is normalized to the amount of total histone H3 present at the
given promoter. ChIP performed with a pan-acetyl H3 antibody showed that over
expression of Cyp33 resulted in a decrease in H3Ac levels at the promoters of MLL
target genes HOXA9 (2 fold), HOXC8 (2 fold) and CDKN1B (5 fold) (Figure 8A). ChIP
for H3K4Me3 (Figure 8B) showed that upon Cyp33 over expression there is a marked
decrease of H3K4Me3 at the promoters of MLL target genes HOXA9 (3.7 fold), HOXC8
(6.5), and CDKN1B (11.3 fold).
The Cyp33 mediated decrease in H3K4Me3 marks at MLL target gene promoters
may be due to active demethylation of H3K4Me3 marks. JARID1 family proteins are
histone demethylases that demethylate H3K4Me3 and H3K4Me2 33,34. To determine if
Cyp33 mediated decrease in H3K4Me3 involved JARID1 histone demethylases, ChIP for
JARID1A and JARID1B at MLL target gene promoters was performed.
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Figure 9: Effect of Cyp33 on the recruitment of H3K4Me3 demethylases JARID1A
and JARID1B
A. ChIP for JARID1A at MLL target gene
promoters

B. qRT-PCR for JARID1A

p = 0.0004

C. ChIP for JARID1B at MLL target
gene promoters

D. qRT-PCR for JARID1B
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E. ChIP for JARID1B at Housekeeping gene promoters

G. ChIP for JARID1B at CDKN1B
promoter

F. ChIP for JARID1B
at JARID1B promoter

q-RT-PCRfor
showing
knock down of Cyp33
H. qRT-PCR
CYP33
HEK 293T cells

1.2

12

Relative Fold Change in
Gene Expression

Fold Recruitment

10

8
6
4

2
0

0.8

0.4

0

si GFP

si CYP

si GFP

si CYP

Figure A through F 293T cells were transiently transfected with pCep4 (vector)
or pCep4-Cyp33 plasmids and harvested after 48 hours for RNA extraction or
ChIP. A, ChIP for JARID1A at MLL target gene promoters; B, qRT-PCR for
JARID1A; C, ChIP for JARID1B at MLL target gene promoters; D, qRT-PCR
for JARID1B; E, ChIP for JARID1B at house-keeping gene promoters; F, ChIP
for JARID1B at JARID1B promoter. n=3, average of 3 independent experiments,
error bar represent S.D. Figure G and H MSA cells were transiently transfected
with si RNA for GFP or CYP 33 after 48 hours for RNA extraction or for ChIP.
G, ChIP for JARID1B at CDKN1B promoter; H, qRT-PCR for CYP33. n=1, the
error bars are from triplicates from q-PCR.
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Upon Cyp33 over expression there is an increase in recruitment of JARID1A at the
promoters of MLL target genes HOXA9 (4.7 fold), HOXC8 (2.7 fold), and CDKN1B (1.8
fold) (Figure 9A). Also Cyp33 over expression resulted in a pronounced increase on
JARID1B recruitment at the promoters of MLL target genes HOXA9 (14.5 fold), HOXC8
(12.2 fold) and CDKN1B (11 fold) (Figure 9C). As shown by qRT-PCR Cyp33 over
expression did not affect the overall expression of JARID1A and JARID 1B (Figure 9B
and D).
To investigate if the Cyp33 mediated increase in recruitment of JARID1B
occurred specifically at MLL target gene promoters, or also happens at other promoters,
ChIP for JARID1B at the promoters of house-keeping genes like GAPDH, Histone H4,
B-globin and RPL10 was performed (Figure 9E). Similar to MLL target genes, over
expression of Cyp33 resulted in increased recruitment of JARID1B at the promoters of
house-keeping genes. Since JARID1B expression was unaffected by Cyp33 over
expression, there should not be increased recruitment of JARID1B at JARID1B promoter
upon Cyp33 over expression. Hence ChIP for JARID1B at the JARID1B promoter was
performed (Figure 9F). Cyp33 over expression did not increase the recruitment of
JARID1B at JARID1B promoter. This shows that Cyp33 mediated increased recruitment
of JARID1B does not occur globally at all promoters, it occurs at specific promoters, but
not restricted to MLL-target promoters. The effect of Cyp33 over expression on
JARID1B recruitment was confirmed by Cyp33 knock down experiment performed by
Steven Poppen in the laboratory (Figure 9G & 9H). Knock down of Cyp33 resulted in
decrease in JARID1B recruitment suggesting that JARID1B may be a downstream
effector of Cyp33 mediated transcriptional regulation.
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Similar to MLL; both JARID1A and JARID1B have a PHD3. Since Cyp33 RRM is a
ligand for the MLL PHD3, we wanted to know if the same is true for JARID1A and
JARID1B PHD3s. Hence a co-immunoprecipitation was performed in 293T cells (Figure
10). In contrast to MLL, JARID1B does not interact with Cyp33.
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Figure 10: Verification of interaction of Cyp33 and JARID1B in vivo
Co-Immunoprecipitation for FLAG JARID1B and HA Cyp33

293T cells were transfected with indicated plasmids. After 48 hours cells were
lysed in IPH lysis buffer. JARID1B was immuno-precipitated using an anti-FLAG
antibody and immunoblotted for FLAG tagged JARID1B in the1st panel from the
top, and for HA Cyp33 in the 2nd panel from the top. Third and fourth panels are
inputs showing the over expression of FLAG tagged JARID1B and HA Cyp33
respectively. The fifth panel is an immunoblot for actin showing equal amount of
protein is present in both samples. n=2, a representative experiment is shown.
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Figure 11: Effect of PPIase activity of Cyp33 on H3K4Me3 and H3K27Ac levels and
JARID1A and JARID1B recruitment at MLL target gene promoters.

A. ChIP for H3K27Ac and H3K4Me3 at HOXA9 promoter

B. ChIP for H3K27Ac and H3K4Me3 at CDKN1B promoter
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C. ChIP for JARID1A and JARID1B at HOXA9 promoter

D. ChIP for JARID1A and JARID1B at CDKN1B promoter

65
E. qRT-PCR for HOXA9 and CDKN1B

F. qRT-PCR for CYP33

293T cells were transiently transfected with pCep4 (vector), or plasmids coding for
pCep4-Cyp33, pCep4-Cyp33 PPIase mutant and harvested after 48 hours for RNA
extraction and ChIP for H3K4Me3, H3K27Ac, JARID1A and JARID1B followed
by q-PCR. A, ChIP for H3K4Me3 and H3K27Ac at HOXA9 promoter; B, ChIP for
H3K4Me3 and H3K27Ac at CDKN1B promoter; C. ChIP for JARID1A and
JARID1B at HOXA9 promoter; D, ChIP for JARID1A and JARID1B at CDKN1B
promoter. Rabbit IgG was used as a negative control for the pull-down. n=1, error
bar represents +/- S.D from the triplicates of q-PCR; E, qRT-PCR for HOXA9 and
CDKN1B; F, qRT-PCR for CYP33.n=1, error bar represents +/- S.D from the
triplicates of q-PCR.
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Experiments performed by Steven Poppen in our laboratory showed that the
recruitment of transcriptional repressors like HDAC1 and Bmi-1 to the repression domain
of MLL is PPIase dependent. JARID1A and JARID1B are present in complex with
HDAC103–105. Therefore, we wanted to investigate if the PPIase activity of Cyp33 is
required for Cyp33 mediated increased recruitment of JARID1A and JARID1B at MLL
target gene promoters. Over expression of wild type Cyp33 resulted in dramatic increase
in recruitment of JARID1A and JARID1B at MLL target promoters like HOXA9 and
CDKN1B when compared to vector control. Nevertheless, over expression of a mutant
Cyp33 that results in 99% decrease in PPIase activity did not show the increased
recruitment of JARID1A and JARID1B at MLL target promoters (Figure 11 C and D).
Also, the PPIase mutant showed increased H3K4Me3 levels and H3K27Ac levels at the
MLL target gene promoters (Figure 11A and B).
To determine if JARID1B is a transcriptional repressor of MLL target genes,
shRNA mediated knock down of JARID1B was performed in 293T cells and the effect
on the transcription of MLL target genes was measured by qRT-PCR (Figure 12A). The
knock down of JARID1B was verified by qRT-PCR (Figure 12B). About 50% decrease
in the mRNA levels of JARID1B was achieved by shRNA. JARID1B knock down
resulted in about two-fold increase in HOXA9 and about 3.2 fold increase in CDKN1B
transcription, whereas there was no effect on the transcription of other MLL target genes
like Myc and Meis1. Thus JARID1B knock down affected the transcription of a sub-set of
MLL target genes. The striking increase in JARID1B recruitment and a concomitant
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Figure 12: Effect of knock down of JARID1B at MLL target genes

A. qRT-PCR for MLL target genes

B. qRT-PCR for JARID1B

p = 0.0167

p = 0.0024
p = 0.0058
p = 0.0029
p = 0.055

293T cells were stably transfected with plasmids for control shRNA or shRNA
against JARID1B. Stable transfectants were selected in puromycin for 5 days. Cells
were harvested for RNA extraction followed by q RT-PCR for A, MLL target genes;
B, for JARID1B. n=3, average of 3 independent experiments and error bar represents
S.D. p values are from two-tailed unpaired t-test.
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decrease in H3K4Me3 levels at MLL target gene promoters upon Cyp33 over expression,
suggested that JARID1B may be one of the downstream effectors of Cyp33.
To know if JARID1B mediates Cyp33 transcription regulation of MLL target
genes, Cyp33 was transiently over expressed in cells that have shRNA mediated stable
knock down of JARID1B. pCep4 transfection after JARID1B knockdown resulted in
statistically significant increase in expression of HOXA9 (Figure 13A) and CDKN1B
(Figure 13B) when compared to pCep4-Cyp33 transfection in sh control cells. This again
shows that JARID1B is a transcriptional repressor of MLL target genes. Cyp33 over
expression in sh control transfected cells resulted in a statistically significant decrease in
transcription of HOXA9 and CDKN1B when compared to sh control cells transfected with
pCep4. This also reiterates that Cyp33 is a transcriptional repressor of MLL target genes.
If JARID1B is a downstream effector of Cyp33 mediating transcriptional repression of
MLL target genes, over expressing Cyp33 in the absence of JARID1B should not result
in transcriptional repression of MLL target genes. However, Cyp33 over expression in
JARID1B knock down cells resulted in statistically significant transcriptional repression
of HOX A9 and CDKN1B when compared to sh control cells that over express Cyp33
(Figure 13A and 13B). Hence, reducing the levels of JARID1B did not overcome Cyp33
mediated transcriptional repression of MLL target genes. Thus, even if JARID1B is a
transcriptional repressor of MLL target genes; it may not be the only downstream effector
of Cyp33. Over expression of Cyp33 and knock down of JARID1B was verified by qRTPCR for CYP33 and JARID1B (Figure 13C and 13D).
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Figure 13: Effect of knock down of JARID1B and over expression of Cyp33 on
the transcription of MLL target genes
A. qRT-PCR for HOXA9

n.s

B. qRT-PCR for CDKN1B

n.s
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C. qRT-PCR for JARID1B

p = 0.0005
p = 0.0027

D. qRT-PCR for CYP33

293T cells were stably transfected plasmids for control shRNA or shRNA against
JARID1B. Stable transfectants were selected in puromycin for 5 days. Further cells were
transfected with pCep4 (vector) or pCep4-Cyp33 plasmids. After 48 hours, cells were
harvested for RNA extraction followed by qRT-PCR for: A, HOXA9; B, CDKN1B; C,
JARID1B; and D, Cyp33. n=2, average of 2 independent experiments and error bar
represents S.D. n.s means not statistically significant.
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Aim 2: Determine the significance of MLL PHD3 binding to H3K4Me3 vs Cyp33.
In addition to binding to Cyp33, the MLL PHD3 also binds to H3K4Me3. This
binding was reported by us and other groups 26,29,30. All these studies focused on the in
vitro interactions of MLL PHD3 or Cyp33. Hence the biological significance of
H3K4Me3 binding and Cyp33 binding to the MLL PHD3 is yet to be determined. From
all these studies we know which are the amino acids in the MLL PHD3 finger that
contribute to H3K4Me3 binding and Cyp33 binding. Conserved aromatic and
hydrophobic residues in the PHD3 of MLL form a cage that acts as a binding pocket for
H3K4Me3 26,29,30. Chang et al. have shown that the M1585A mutation abrogates
H3K4Me3 binding and resulted in decreased transcriptional activation of MLL target
genes. Unlike the W1594A point mutant, this mutation did not affect the protein stability
30

. Based on this information, we mutated methionine 1585 to alanine (M1585A) as a

candidate mutation to disrupt the binding to H3K4Me3. Wang et al. have shown that
mutating methionine 1606 to aspartate in MLL abolished the binding of MLL PHD3 to
Cyp33 29. Moreover, methionine 1606 does not participate in H3K4Me3 binding. Hence
M1606D mutation should not interfere with H3K4Me3 binding and was used as a
candidate mutation that disrupts MLL PHD3 binding to Cyp33.
MLL is required for normal hematopoiesis 6,7,67,106. In order to understand the
biological significance of MLL PHD3 binding to H3K4Me3 versus Cyp33, we wanted to
study the effect of the mutations in the context of a full length MLL protein in
hematopoietic progenitor colony formation assay. But MLL is a big protein and the
cDNA is about 14KB long. Therefore, it will be difficult to mutate, clone and will be
impossible to package such a big construct in retro viruses. MLL is proteolytically
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cleaved into MLL-N and MLL-C; the fragments interact with each other through their
FYRN and FYRC domains, and MLL-C stabilizes MLL-N 36,37,74. The N-fragment has
the PHD3 finger that binds to H3K4Me3 and the C-fragment has the H3K4Me3 methyl
transferase activity. To circumvent the practical problems of expressing a big construct,
the mutations were made in a DNA sequence encoding the MLL-N fragment instead of
full length MLL. FLAG tagged MLL-N from the pCI-MLL-N provided by Dr. James
Hsieh was cloned into MSCV neo by Wei Wei in our laboratory. MSCV neo FLAG
MLL-N M185A and M1606D were generated in this study by site-directed mutagenesis
in a smaller fragment of MLL-N, and swapped into MSCV MLL-N wt as explained in the
Methods section.
To date, the interaction of the MLL PHD3 with H3K4Me3 has been only
demonstrated in vitro. To determine if MLL-N wt (which has the PHD3) binds to
H3K4Me3 in vivo, a nucleosome pull down assay was performed. If MLL-N (through its
PHD3) binds to H3K4Me3, then it would co-immunoprecipitate with nucleosomes that
are trimethylated at H3K4. Partial digestion of the chromatin fraction with micrococcal
nuclease will result in induction of double stranded breaks of DNA in the nucleosome
linker region, releasing mononucleosomes. Enrichment for the mononuclesome fraction
was optimized by varying the time and temperature of digestion. To standardize the
micrococcal nuclease assay, chromatin was isolated from 293T cells as explained in
methods section and the micrococcal nuclease digestion was performed at the indicated
time and temperature (Figure 14B). About 146 bp of DNA are wound around a
mononucleosome. To verify mononucleosome enrichment, the DNA was purified from
proteins and loaded onto a 2% agarose gel containing ethidium bromide. DNA fractions,
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with an average length of about 150 bp were obtained by performing the digestion at
37°C for 4 minutes and 30 seconds (Figure 14B).
A nucleosome Co-IP of FLAG MLL-N and H3K4Me3 was performed (Figure
14C). FLAG MLL-N co-immunoprecipitated with trimethylated H3K4, whereas the
vector control did not. This shows that there is no non-specific binding of the
nucleosomes to the protein A conjugated FLAG beads. To ensure that there is equal
amount of H3K4Me3 containing nucleosomes present in the nucleosome preparations, a
Western blot for H3K4Me3 was performed (Figure 14C). After establishing the
conditions of the nucleosome Co-IP with MLL-N wt, the binding status of M1585A and
M1606D mutants to H3K4Me3 was determined using the same assay. The micrococcal
digestion and the release of mononucleosomes were verified (Figure 15B). A nucleosome
Co-IP of FLAG MLL-N or the mutants with H3K4Me3 performed (Figure 15C) showed
that both MLL-N wt and the M1606D mutant co-immunoprecipitated with nucleosomes
containing H3K4Me3. In contrast, the M1585A mutant behaved similar to that of the
vector control (negative control). Hence a M1585A mutation in the PHD3 of MLL-N
abrogates binding to H3K4Me3 marked nucleosomes.
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Figure 14: Verification of binding of MLL-N wt to H3K4Me3 nucleosomes in vivo

A, Schematic of Nucleosome pull-down assay; B, Standardization of microcoocal
nuclease digestion was performed in untransfected 293T cells. Enrichment for
mononucleosomes was verified by agarose gel, n=1; C, Nucleosome Co-ip, 293T cells
were transiently transfected with FLAG MLL-N wt, cells or MSCV neo (Vector)
plasmids. Cells were harvested after 48 hrs for micrococcal digestions at 37C for 4 min
30” followed by nucleosome pull down assay. FLAG tagged MLL-N was
immunoprecipitated with anti-FLAG agarose beads and immunoblotted for H3K4
trimethylated nucleosomes with anti H3K4Me3 antibody, n=2, a representative
experiment is shown.
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Figure 15: Binding status of M1585A and M1606D to H3K4Me3 nucleosomes in vivo

293T cells were transfected with MSCV neo (E) or FLAG tagged MLL-N wt (wt),
M1585A (MA), M1606D (MD) plasmids. Cells were harvested after 48 hrs for a
nucleosome pull down assay: A, Schematic of binding of MLL-N wt and mutants to
H3K4Me3 and Cyp33; B, Micrococcal nuclease digestion performed to enrich for
mononucleosomes which was verified by DNA agarose gel, (MW means DNA
molecular weight marker); C, Nucleosome Co-IP Nucleosome Co-IP: FLAG tagged
MLL-N was immunoprecipitated with anti-FLAG agarose beads and immunoblotted for
H3K4 trimethylated nucleosomes with anti H3K4Me3 antibody. MW means n=2, a
representative experiment is shown.
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The binding status of MLL-N wt, or the mutants, to Cyp33 was determined using
a GST pull down experiment, by Dr. Osmers in our laboratory. As expected the MLL-N
wt and M1585A mutant both bind Cyp33, but the M1606D mutation does not.
H3K4Me3 is a transcriptional activation mark. Hence, MLL PHD3 binding to
H3K4Me3 may protect H3K4Me3 from being targeted by histone demethylases.
Furthermore, MLL is a writer of H3K4Me3 marks. Hence, MLL PHD3 binding to
H3K4Me3 may help MLL-C in the propagation of methyl marks to adjacent
nucleosomes. Both these scenarios should result in an increase in H3K4Me3 marks at
MLL target gene promoters. As a consequence, MLL PHD3 binding to H3K4Me3 should
result in transcriptional activation of MLL target genes and abrogating the binding should
result in decrease in transcription of MLL target genes.
From in vitro binding studies, it is known that Cyp33 has a higher affinity for
MLL PHD3 than H3K4Me3 and Cyp33 in excess reduces the affinity of MLL PHD3 for
H3K4Me3 26. Cyp33 over expression in our studies also resulted in a decrease of
H3K4Me3 marks and increased recruitment of JARID1B histone demethylases at MLL
target gene promoters. Hence abrogating Cyp33 binding in MLL PHD3 should reduce the
exposure of H3K4Me3 to the JARID1B histone demethylase, resulting in an increase in
H3K4Me3 marks and increase in transcription of MLL target genes. In short, the
hypothesis of the second aim of this study is that MLL PHD3 binding to H3K4Me3
contributes to transcriptional activation, while MLL PHD3 binding to Cyp33 contributes
to transcriptional repression of MLL target genes.
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Figure 16: Verification of over expression of MLL-N

A. qRT-PCR for MLL

B. Western Blot for FLAG tagged MLL-N and Mutants

MEFs (MLL +/+) were transduced with MSCV neo (Vector), MLL-N wt, M1585A or
M1606D (in the presence of endogenous MLLC) and selected with G-418 for 11
days. Cells were harvested for RNA followed by: A, qRT-PCR for human MLL. n=3,
average of 3 independent experiments; B, Immunoblot for FLAG tagged MLL-N and
mutants. n=2, a representative experiment is shown.
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To test the above mentioned hypothesis, MEF (Mll+/+) were transduced with
MSCV neo (Vector), MLL-N wt., M1585A or M1606D expressing retro-viruses and the
effect on target gene expression was assessed by qRT-PCR. Over expression of MLL-N
wt and mutants was verified by qRT-PCR (Figure 16A). MLL transcripts were
normalized to Actb transcripts levels. There is about the same level of over expression of
MLL-N wt and mutants. Over expression of MLL-N at the protein level was verified by
immunoblot for FLAG tag (Figure 16B).
The effect of over expression of MLL-N wt and mutant on target gene expression
was measured by qRT-PCR (Figure 17). Over expression of MLL-N wt resulted in a
statistically significant increase in transcription of the MLL target genes like Hoxa9,
Hoxc8, and Cdkn1b when compared to the vector control. The p values from one sample
Student’s t test when compared between vector and MLL-N wt for Hoxa9, Hoxc8 and
Cdkn1b are 0.0068, 0.0097, and 0.0087 respectively. Over expression of M1606D mutant
(that does not bind Cyp33) resulted in transcriptional activation of Hoxa9, Hoxc8 and
Cdkn1b, a trend similar to that of MLL-N wt over expression. However, the p values
from one sample student’s t test when compared between vector and M1606D for Hoxa9,
Hoxc8 and Cdkn1b are 0.0646, 0.0204 and 0.0495 showed that the statistically significant
transcriptional activation was observed only for Hoxc8 and Cdkn1b but not for Hoxa9.
Additionally, the M1606D mutation did not result in increased transcription of MLL
target genes over the MLL-N wt over expression.
In contrast to MLL-N wt and M1606D mutant, over expression of MLL-N
M1585A (that does not bind H3K4Me3) did not have any effect on transcription of MLL
target genes when compared to the vector control. However, M1585A over expression
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resulted in a decrease in transcription of MLL target genes when compared to MLL-N wt
and its M1606D mutant. The p values from two-tailed unpaired student’s t-test compared
between M1585A and MLL-N wt for Hoxa9, Hoxc8 and Cdkn1b are 0.0063, 0.0025 and
0.0037 respectively. The p values from two-tailed unpaired student’s t-test compared
between M1585A and M1606D for Hoxa9, Hoxc8 and Cdkn1b are 0.0352, 0.012 and
0.0094 respectively. This shows that MLL PHD3 binding to H3K4Me3 contributes to the
transcriptional activation of MLL target genes.
Since MLL-N wt over expression resulted in transcriptional activation of MLL
target genes, I hypothesized that MLL-N over expression resulted in increased protein
stability of MLL-C or nuclear import of MLL-C. To test this, MEFs were transduced with
MSCV neo (vector), or MLL-N wt, M1585A and M1606D retro-viral expression
constructs and cells were harvested for nuclear lysate preparation. Further, a Western blot
for MLL-C (Figure 18A) showed that MLL-N wt over expression did not increase MLLC protein levels. Alternatively, I hypothesized that MLL-N wt over expression increased
the recruitment of MLL-C at MLL target gene promoters, thus leading to increase in
transcription of MLL target genes. Hence a ChIP for MLL-C at the Hoxa9 promoter was
performed in (Figure 18B). MLL-N wt over expression resulted in a statistically
significant increase in MLL-C recruitment at the Hoxa9 promoter when compared to the
vector control (one sample student’s t-test p = 0.031), M1585A (unpaired student’s t- test
p = 0.0017 and M1606D (unpaired student’s t- test p = 0.0322). However there is no
increase in MLL-C recruitment upon MLL-N wt over expression at the house-keeping
gene promoter, Actb promoter (Figure 18C). Unlike MLL-N wt over expression,
M1585A over expression did not result in increase in MLL-C recruitment at the Hoxa9
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Figure 17: Effect of MLL-N wt and mutants over expression on transcription of
MLL target genes
qRT-PCR for MLL target genes

MEFs (MLL +/+) were transduced with MSCV neo (Vector), MLL-N wt, M1585A or
M1606D retroviruses (in the presence of endogenous MLLC) and selected with G418 for 11 days. Cells were harvested for RNA preparation followed by quantitative
RT-PCR for MLL target genes. n=3, average of 3 independent experiments, error bars
represent S.D. Pairwise comparisons between M1585A and MLL-Nwt ; M1585A and
M1606D were performed by two-tailed unpaired Student’s t-test. ** - Decrease in
transcription of MLL target genes in M1585A is statistically significant when
compared to MLL-N wt (Hoxa9- p = 0.0063, Hoxc8- p = 0.0025, Cdkn1b- p = 0.037)
and M1606D (Hoxa9- p = 0.0352, Hoxc8- p = 0.012, Cdkn1b- p = 0.0094).
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Figure 18: Effect of MLL-N and mutant over expression on MLL-C recruitment

A. Western Blot for MLL-C

B. ChIP for MLL-C at Hoxa9 promoter

Loading Control

C. ChIP for MLL-C at Actb promoter

MEFs (MLL +/+) were transduced with MSCV neo (Vector), MLL-N wt, M1585A or
M1606D retroviruses (in the presence of endogenous MLLC) and selected with G-418 for
11 days. Cells were harvested for: A, Immunoblot for MLL-C, Cells were lysed for nuclear
lysate preparation, followed by immunoblot for MLL-C, n=1; B, ChIP for MLL-C at the
Hoxa9 promoter. Pairwise comparisons were performed by either one sample or unpaired
two-tailed student’s t-tests. * means increase in MLL-C recruitment in MLL-N wt when
compared to vector (one sample student’s t test p = 0.031) and M1585A (unpaired student’s
t- test p = 0.0017). ** means decrease in MLL-C recruitment in M1606D when compared to
MLL-N wt (unpaired student’s t- test p = 0.0322) and to M1585A (unpaired student’s t- test
p = 0.0011). C, ChIP for MLL-C at Actb promoter. n=3, average of 3 independent
experiments, error bar represents S.D.
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promoter when compared to vector control. The p value from one sample student’s t-test
performed between vector control and MLL-N wt is 0.1421. This shows that MLL PHD3
binding to H3K4Me3 may be involved in the recruitment of MLL-C to Hoxa9 promoter.
Surprisingly, the M1606D mutant (that does not bind Cyp33) showed a decrease in
recruitment of MLL-C at the Hoxa9 promoter when compared to, M1585A (unpaired
student’s t- test p = 0.0011) and MLL-N wt (unpaired student’s t- test p = 0.0322).
Since over expression of MLL-N wt and M1606D mutant resulted in
transcriptional activation of MLL target genes but M1585A did not, we hypothesized that
MLL PHD3 binding to H3K4Me3 contributes to transcriptional activation of MLL target
genes. This may be because, MLL PHD3 binding to H3K4Me3 protects H3K4Me3 from
being demethylated by histone demethylases and/or helps in propagation of methyl marks
to adjacent nucleosomes. Both the above mentioned scenarios should result in increased
H3K4Me3 at MLL target genes resulting in increased transcriptional activation of MLL
target genes. To calculate the fold enrichment for H3K4Me3 at a given promoter, the
amount of H3 present at a given promoter should be determined. A ChIP for histone H3
at MLL target genes was performed (Figure 20A). MLL-N wt and mutant over
expression did not significantly affect the total H3 levels both at MLL target genes and
Actb promoter (Figure 19 A & B).
After determining the histone H3 density at MLL target genes, a ChIP for
H3K4Me3 at MLL target gene promoters was performed (Figure 20A). Over expression
of MLL-N wt resulted in an increase in H3K4Me3 marks relative to vector control at the
Hoxa9 promoter, but did not show a statistically significant increase at the Cdkn1b
promoter. The p values from one sample student’s t-test are 0.0067 and 0.1187
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respectively. Over expression of MLL-N wt also resulted in a statistically significant
increase relative to the M1585A mutant in H3K4Me3 marks at the Hoxa9 (unpaired
student’s t-test p =0.001) and Cdkn1b (unpaired student’s t-test p =0141) promoters but
not at the Actb promoter (Figure 20B). Abrogating H3K4Me3 binding resulted in a
decrease in H3K4Me3 marks, a decrease in MLL-C recruitment and decrease in target
gene expression. These results together suggest that MLL PHD3 binding to H3K4Me3,
helps MLL-C to methylate adjacent nucleosomes. The M1606D mutant did not show a
significant increase in H3K4Me3 marks over the vector control and the M1585A mutant.
This may be a result of decreased recruitment of MLL-C at the MLL target promoters
(Figure 20A).
Next, to determine if MLL PHD3 binding to H3K4Me3 protects H3K4Me3 from
histone demethylases, MLL-N wt or its mutants were over expressed, and recruitment of
the JARID1B histone demethylase at the MLL target gene promoters was measured by
ChIP. If MLL PHD3 binding to H3K4Me3 protects H3K4Me3 from histone
demethylases, then abrogating MLL PHD3 binding to H3K4Me3 should result in
increased recruitment of JARID1 histone demethylases at MLL target gene promoters.
There was no significant difference between vector control, MLL-N wt and M1585A in
the recruitment of JARID1B at Hoxa9 promoter (Figure 21A). This shows that in the
system used, MLL PHD3 binding to H3K4Me3 does not protect H3K4Me3 from
JARID1B binding. M1606D over expression resulted in a statistically significant
decrease in the recruitment of JARID1B at the Hoxa9 promoter when compared to the
vector control (one sample t-test p = 0.0046, MLL-N wt (unpaired student’s t-test p =
0.034) or M1585A (unpaired student’s t-test p = 0.0351).
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Figure 19: Effect of over expression of MLL-N wt and mutants on histone H3
density
A. ChIP for Histone H3 at MLL target gene promoters.

B. ChIP for Histone H3 at Actb promoter.

MEFs (MLL +/+) were transduced with MSCV neo (Vector), MLL-N wt, M1585A or
M1606D (in the presence of endogenous MLLC) and selected with G-418 for 11 days and
harvested for ChIP for histone H3 at: A, MLL target gene promoters, B, Actb promoter
was performed. n=3, average of 3 independent experiments, error bars represent S.D.
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Figure 20: Effect of over expression of MLL-N wt and mutants on H3K4Me3 marks

A. ChIP for H3K4Me3 at MLL target gene promoters

B. ChIP for H3K4Me3 at Actb promoter.

MEFs (MLL +/+) were transduced with MSCV neo (Vector), MLL-N wt, M1585A
or M1606D (in the presence of endogenous MLLC) and selected with G-418 for 11
days and harvested for ChIP for histone H3K4Me3 at A, MLL target gene promoters,
B, Actb promoter in figure B was performed. n=3, average of 3 independent
experiments, error bars represent S.D. * Decrease in H3K4Me3 levels in M1585A at
the Hoxa9 (unpaired student’s t-test p =0.001) and Cdkn1b (unpaired student’s t-test
p =0141) when compared to MLL-N wt.
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Figure 21: Effect of over expression of MLL-N wt and mutants on JARID1B
recruitment
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MEFs (MLL +/+) were transduced with MSCV neo (Vector), MLL-N wt, M1585A or
M1606D (in the presence of endogenous MLLC) and selected with G-418 for 11 days
and harvested for ChIP for: A, JARID1B at MLL target gene promoters. *- Decrease in
JARID1B recruitment when compared to vector control (one sample t-test p = 0.0046)
MLL-N wt- p = 0.034 and M1585A- p = 0.0351; B, JARID1B at Actb promoter. n=3,
average of 3 independent experiments, error bars represent S.D.
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Figure 22: Verification of over expression of MLL-N wt and mutants in mouse
hematopoietic progenitors

qRT-PCR for MLL

C kit + mouse hematopoietic progenitors isolated from mouse bone marrow were retro
virally transduced with MSCV neo (Vector), MLL-N wt, M1585A, and M1606D and
grown in RPMI containing IL-3, IL-6, SCF, GM-CSF and selected with G418 for 3 days.
The cells were harvested for RNA extraction followed by qRT-PCR for human MLL.
n=3, average of 3 independent experiments, error bars represent S.D.
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Figure 23: Effect of over expression of MLL-N wt and mutants on MLL target gene
expression in Ckit+ve mouse hematopoietic progenitors

Transduction and selection as explained in Figure. Cells were harvested for RNA
extraction. qRT-PCR for MLL target genes was performed. *- Statistically
significant decrease in expression of Hoxa9 and Meis1 in Vector and M1585A when
compared to MLL-N wt over expression. ** Statistically significant increase in
expression of Cdkn1b and Cdkn1a in M1585A when compared to Vector, M1585A
and M1606D. n=3, average of 3 independent experiments, error bars represent S.D.
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Hence, abrogating MLL PHD3 binding to Cyp33 (M1606D) resulted in decreased
recruitment of histone demethylases at MLL target gene promoters whereas at the Actb
promoter there was no significant decrease.
Since over expression of MLL-N wt or mutants had an effect on MLL target
genes in MEFs, I wanted to determine the effect of over expression of MLL-N wt and its
mutants in mouse hematopoietic progenitors. Over expression of MLL-N wt, its mutants
M1585A and M1606D in C-kit+ mouse hematopoietic progenitors after retro viral
transduction was verified by qRT-PCR for human MLL normalized to Actb. The data in
Figure 23 shows that MLL-N wt, M1585A and M1606D are expressed at about equal
levels in hematopoietic progenitors.
Having confirmed that the retro-viral transductions have worked in hematopoietic
progenitors the effect of over expression of MLL-N wt and mutants on target gene
expression was assessed by qRT-PCR (Figure 23). Similar to MEF, over expression of
MLL-N wt and M1606D in hematopoietic progenitors resulted in statistically significant
increase in expression of Hoxa9 when compared to vector and M1585A. The p value,
from Student’s t-test, when comparing between MLL-N wt and M1585A over expression
is 0.0056. The p value for M1606D and M1585A is 0.0243. Over expression of MLL-N
wt and M1606D also resulted in increased transcription of Meis1 when compared to
vector and M1585A. This shows that MLL PHD3 binding to H3K4Me3 in hematopoietic
progenitors contributes to transcriptional activation of MLL target genes.
Like Hoxa9 and Meis1, Cdkn1a and Cdkn1b are known targets of MLL 10,11. In
contrast to Hoxa9 and Meis1, over expression of MLL-N wt did not increase the
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transcription of Cdkn1b and Cdkn1a. Whereas the over expression of M1585A resulted in
increased expression of Cdk1b and Cdkn1a. The expression of Pu.1 remained unaffected
by MLL-N and mutant over expression. Hoxa9 and Meis1 expression keeps the
hematopoietic progenitors in an undifferentiated state. Upon differentiation their
expression decreases. Since MLL PHD3 binding to H3K4Me3 contributes to
transcriptional activation of Hoxa9 and Meis1, we tested the effects of MLL-N wt on
hematopoiesis using an in vitro colony formation assay. If the cells are in undifferentiated
state, each progenitor would undergo multiple cell divisions giving rise to a colony in
methyl cellulose. This assay is a measure of the proliferation potential of hematopoietic
progenitors. A portion of transduced Ckit+ mouse hematopoietic progenitors used in the
previous experiment (Figure 23) were plated on methyl cellulose containing IL-3, IL-6,
GM-CSF and SCF. The successful transduction and over expression of MLL-wt and
mutants was verified (Figure 22). When compared to vector control transduced cells,
MLL-N over expression resulted in a decrease in colony formation. Considering the fact
that the MSCV neo MLL-N retroviral expression construct is at least twice longer than
the MSCV neo vector, the differences in the viral titer and expression of neo-resistance
will affect the colony formation. Since MLL-N wt, M1585A and M1606D are the same
molecular weight and they have about equal levels of expression, I compared the colony
formation potential of MLL-N wt to that of the mutants. M185A over expression resulted
in a drastic reduction in colony formation when compared to MLL-N wt and vector
control (Figure 24); over expression of the M1606D mutant showed no difference with
MLL-N wt. Hence MLL PHD3 binding to H3K4Me3 contributes to MLL’s function in
hematopoiesis.
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Figure 24: Effect of over expression of MLL-Nwt and mutants on the colony
formation potential of hematopoietic progenitors
Hematopoietic Progenitors Colony Formation Assay.

n.s

Ckit+ve selection and transduction as explained in Figure. Transduced cells were
selected with G418 on a methyl cellulose plate containing IL-3, IL-6, SCF, and GMCSF for 7 days. Colonies were counted on Day7. n=3, average of 3 independent
experiments, error bar represents S.D. Pairwise comparisons were performed by
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Figure 25: Effect of MLL-N wt and mutants over expression on colony formation of
MLL-AF9 transformed hematopoietic progenitors

Hematopoietic Progenitor Colony Formation Assay.

C-kit+ve hematopoietic progenitors were isolated from mouse bone marrow,
transduced with MSCV puro MLL-AF9 retoviruses, selected for a week in
puromycin and grown in RPMI containing IL-3, IL-6, SCF and GM-CSF .
Further, cells were transduced with MSCV neo (Vector), MLL-N wt, M1585A or
M1606D retroviruses and plated on methyl cellulose containing G418, IL-3, IL6, SCF, and GM-CSF. Colonies were counted on Day7. The cells were recovered
and re-plated on methyl cellulose. The figure above is from week3 re-plating.
Representative colony images are shown. n=2, average of two independent
experiments, error bar represents S.D.
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The results from this study revealed that MLL PHD3 binding to H3K4Me3
contributes to transcriptional activation of genes that regulate hematopoiesis. Recent
studies showed that the MLL wt allele is required for MLL-fusion mediated
leukemogenesis 20,40. The MLL-fusion protein lacks the 3rd PHD finger. But the MLL wt
allele has the PHD3 intact. To know if MLL PHD3 (present in MLL wt) binding to
H3K4Me3 contributes to MLL fusion mediated leukemogenesis, the effect of
overexpression of MLL-N wt and the mutants on colony formation by MLL-AF9
transformed hematopoietic progenitors was tested (Figure 25). Over expression of MLLN or the mutants did not affect the colony formation of MLL-AF9 transformed
hematopoietic progenitors in the assay conditions tested.

CHAPTER 5
DISCUSSION
Many chromatin associated proteins have tandem PHD fingers that mediate DNA
binding, histone binding or serve as domains for other protein-protein interactions. MLL
has 3 tandem PHD fingers. More than a decade ago, studies from our lab identified
Cyp33 as a ligand for MLL PHD3. Cyp33 over expression resulted in transcriptional
repression of MLL target genes 23,57. Thus Cyp33 over expression switches MLL from a
transcriptional activator to a repressor. Recently we, and two other groups reported that
the MLL PHD3 binds to trimethylated H3K4 (H3K4Me3) 26,29,30. Since H3K4Me3 is a
transcriptional activation mark, we hypothesized that binding of MLL PHD3 to
H3K4Me3 protects it from histone demethylases which would result in transcriptional
activation of MLL target genes. Thus the PHD3, a small 60 amino acids long region of
MLL can potentially act as a molecular switch in regulation of transcription of its target
genes.
In vitro binding studies performed by our collaborator Dr. Bushweller, showed
that when Cyp33 is in excess, it reduces the affinity of the MLL PHD3 for H3K4Me3 26.
To determine if this is true in vivo, I sought to test the effect of Cyp33 over expression in
293T cells on H3K4Me3 methylation and binding of histone demethylases to MLL target
gene promoters. Previous studies employed a semi- quantitative approach to measure
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gene expression 23, while this study employs qRT-PCR, a quantitative method to measure
gene expression. Since a different technique was used than in previous studies, before
doing ChIP for H3K4Me3, the effect of Cyp33 over expression on transcription of MLL
target genes was first confirmed. We confirmed that Cyp33 over expression resulted in a
decrease in transcription of MLL target genes. However, the effect of Cyp33 over
expression on transcription is not exclusive of MLL target genes. Except for β2M, other
house-keeping genes, which are not MLL target genes, also showed transcriptional
repression upon Cyp33 over expression. Recently, Steven Poppen from our lab has
shown that both over expression and knock down of Cyp33 resulted in slow growth of
cells in culture. This suggests that altering the levels of Cyp33 in the cell may have an
effect on general metabolism of the cell. Besides, binding to MLL PHD3, Cyp33 is
known to be present in the spliceosome complex 107. Hence the effect of Cyp33 over
expression on transcription of house-keeping genes may be MLL dependent or MLL
independent.
Having confirmed that Cyp33 over expression resulted in decreased expression of
MLL target genes, I wanted to determine the effect of excess of Cyp33 on H3 density,
transcriptional activation and repressive histone marks. H3 density reflects the closed or
open status of the chromatin for access to the RNA POLII transcriptional machinery.
Cyp33 over expression resulted in increased H3density at MLL target gene promoters,
which indicates a closed chromatin state and is consistent with the transcriptional
repression of target genes. One of the possible mechanisms of Cyp33 mediated
transcriptional repression of MLL target genes, is through increased recruitment of corepressors like HDAC1 and Bmi-1 to the repression domain of MLL 27. Results from this
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study show that Cyp33 over expression results in a decrease in H3 acetylation marks
which can be explained by the increased recruitment of HDAC to the repression domain
of MLL.
Like H3Ac, increased H3K4Me3 at the promoter region is linked to
transcriptional activation. As mentioned earlier, from in vitro binding studies, it is known
that when Cyp33 is in excess, it reduces the affinity of the MLL PHD3 for the H3K4Me3
histone mark 26. In vivo the scenario is more complicated. The 3rd PHD finger of the
JARID1A and JARID1B histone demethylases is also known to bind H3K4Me3 35,101.
The reduced affinity of the MLL PHD3 for H3K4Me3 after binding of Cyp33 may allow
histone demethylases or other competing ligands to bind this histone mark. According to
this hypothesis, Cyp33 over expression should result in increased recruitment of
JARID1A and JARID1B histone demethylases and consequent decrease in H3K4Me3
marks. Results from our ChIP experiment showed that Cyp33 over expression resulted in
increased recruitment of JARID1A and JARDI1B and a corresponding decrease in
H3K4Me3 marks at MLL target gene promoters which is in agreement with our
hypothesis.
Concordant with its effects on the transcription of house-keeping genes, Cyp33
over expression also resulted in increased recruitment of JARID1B at house-keeping
gene promoters. However, Cyp33 over expression did not affect the transcription of
JARID1A and JARID1B nor did it increase the recruitment of JARID1B at the JARID1B
promoter. This suggests that the effect of Cyp33 over expression on transcription may not
be a global phenomenon and occurs at a subset of genes. Knock down of Cyp33 in an
experiment performed in collaboration with Steven Poppen showed a significant decrease
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in JARID1B recruitment at MLL target gene promoters which is the opposite of what we
observe when over expressing Cyp33.
Cyp33 when present in excess, besides exposing the methyl marks to JARID1
histone demethylases, can also increase the recruitment of JARID1 histone demethylases
at MLL target genes by other mechanisms. When compared to JARID1A, JARID1B
recruitment is more pronounced upon Cyp33 over expression. JARID1B directly interacts
with Class I and Class II HDACs and with hPC2 105,108, but there are no studies so far
showing a direct interaction of JARID1A with HDAC and hPC2. As mentioned earlier,
Cyp33 over expression, augments the recruitment of transcriptional co-repressors like,
HDAC1 and Bmi1 to the repression domain of MLL 27. It is certainly a possibility that
along with other co-repressors Cyp33 may also bring in JARID1B to the repression
domain of MLL.
Another mechanism by which Cyp33 can increase the recruitment of JARID1A
and JARID1B at MLL target promoters is through directly binding to JARID1A and
JARID1B. Besides the PHD finger of MLL, PHD fingers present in other proteins are not
known to bind Cyp33. JARID1A and JARID1B have 3 PHD fingers. Results from this
study shows that Cyp33 does not co-immunoprecipitate with JARID1B.
Cyp33 is a prolyl isomerase, inhibiting the prolyl isomerase activity by
Cyclosporin A, deleting the Cyclophilin domain that encodes for the PPIase, or over
expressing a prolyl isomerase deficient mutant of Cyp33, does not result in
transcriptional repression of MLL target genes 23,26. This shows that the PPIase activity of
Cyp33 is required for the transcriptional repression of MLL target genes. Additionally,

98
the PPIase activity is required for the recruitment of transcriptional repressors like
HDAC1 and Bmi1 to the repression domain of MLL. Like HDAC1 and Bmi-1,
JARID1A and JARID1B are transcriptional repressors and are present in complex with
HDAC. The results from this study show that recruitment of JARID1A and JARID1B is
PPIase dependent. Furthermore, over expression of the PPIase mutant results in decrease
in H3K4Me3 levels and H3K27Ac levels at MLL target gene promoters. Though we
were not able to pin point the exact mechanism of Cyp33 mediated increased recruitment
of JARID1A and JARID1B to the chromatin, we have identified the requirement of
PPIase activity of Cyp33 for JARID1A and JARID1B recruitment at MLL target gene
promoters.
Since Cyp33 over expression studies suggested a role for JARID1B in
transcriptional regulation of MLL target genes, shRNA knock down of JARID1B was
performed in 293T cells. Knock down of JARID1B resulted in increased expression of
HOXA9 and CDKN1B, indicating that JARID1B is a transcriptional repressor of a sub-set
of MLL target genes. Only 50% reduction in JARID1B expression was achieved by our
knock down. If the efficiency of the knock down was improved, there may be an effect
on the expression of other MLL target genes like HOXC8 and MYC. JARID1A and
JARID1B are redundant in H3K4Me3 demethylation 31. The loss of JARID1B can be
functionally compensated by JARID1A. Hence a combination of JARID1A and
JARID1B knock down may have a greater effect on MLL target gene expression.
Cyp33 over expression studies and JARID1B knock down studies suggest that
JARID1B is a downstream effector of Cyp33. If JARID1B is a downstream effector of
Cyp33-mediated transcriptional regulation of MLL target genes, knock down of
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JARID1B should overcome the transcriptional repression resulting from Cyp33 over
expression. But our results show that Cyp33 over expression, even after the knock down
of JARID1B, resulted in transcription repression of MLL target genes. From this
experiment we cannot conclude if JARID1B is a downstream effector of MLL target
genes. The caveat of this experiment is that JARID1B may not be the only downstream
effector of Cyp33. As mentioned earlier, there is redundancy in the function of JARID1A
and JARID1B, and even the knockdown of JARID1B was incomplete. The ideal
experiment to do would be to over express Cyp33 in a cell line that is null for JARID1A
and JARID1B (MEF JARID1A-/- , JARID1B -/-). Since Cyp33 can also operate through
other transcriptional co-repressors like HDAC1at MLL target gene promoters, it may be
difficult to prove JARID1B as one of the downstream effectors of Cyp33.
The results from the first aim of this study demonstrated the effects of excess of
Cyp33 on MLL target gene expression and more specifically on H3K4 trimetylation. The
biological significance of MLL PHD3 binding to H3K4Me3 and Cyp33 is not known.
Chang et al., have shown that the abrogation of H3K4Me3 binding to MLL PHD3
resulted in decreased transcriptional activation of MLL target genes 30. MLL is a
transcriptional regulator of genes involved in hematopoiesis. To determine the biological
significance of MLL PHD3 binding to H3K4Me3 versus Cyp33, the effect of abrogation
of binding was studied using an in vitro colony formation assay of hematopoietic
progenitors. To do so, retroviral transduction of wild type MLL-N, and MLL-N mutants,
in mouse hematopoietic progenitors was performed. Due to its molecular weight, it is
difficult to package full length MLL cDNA in a retro viral vector. MLL is proteolytically
cleaved into MLL-N and MLL-C by TASPASE-1. The PHD3 in MLL-N is the reader of

100
H3K4Me3 and the SET domain in MLL-C is the writer for H3K4Me3. Thus by making
mutations in MLL-N fragment, instead of full length MLL, will allow us to precisely
study the effects of abrogation of the reader function without over expressing the writer.
Furthermore, it will also help to overcome the practical difficulties of using a very big
construct for retro viral packaging.
Similar to the PHD fingers of BPTF and ING family members that bind
H3K4Me3, the conserved aromatic residues in MLL PHD3 form an aromatic cage which
is the binding pocket for H3K4Me3. Chang et al. have shown that this mutation resulted
in decreased binding of H3K4Me3 without affect the protein stability 30. Hence this was
chosen as a candidate mutation that would abrogate the binding of MLL PHD3 to
H3K4Me3. The H3K4Me3 binding site and Cyp33 binding site in MLL PHD3 are
distinct, but very close to each other. Hence abrogating one binding may affect the other.
Wang et al. showed that the M1606D mutation abolished the binding of MLL PHD3 to
Cyp33. However the effect of this mutation on H3K4Me3 binding is not known. Before
doing any hematopoietic progenitor colony formation assays, the binding of MLL-wt,
M1585A, and M1606D mutants to H3K4Me3 in vivo was characterized. The results from
nucleosome Co-IP showed that the MLL-N wt and M1606D mutant coimmunoprecipitated with nucleosomes trimethylated on H3K4 whereas the M1585A
mutant MLL-N did not.
To date, there are no studies on the effect of overexpression of MLL-N wt on
target gene expression. To study this and to know the effect of MLL-N mutants on target
gene expression, over expression of MLL-N wt and mutants was induced in MEFs using
retroviral expression constructs. Hsieh et al., have shown that MLL-C is required for the
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stability of MLL-N 74. Based on this finding, over expressing just the MLL-N fragment
should result in degradation of excess of MLL-N. Therefore over expression of MLL-N
wt should not have much effect on target gene expression. Surprisingly, MLL-N wt over
expression resulted in increased MLL target gene expression both in MEF and in
hematopoietic progenitors. Yokoyoma et al., have shown that free MLL-C in the nucleus
is targeted for proteosomal degradation in the cytoplasm 38. If the endogenous levels of
MLL-C are not limiting, and over expression of MLL-N enhances the MLL-N-C holocomplex formation in the nucleus, then upon over expression of MLL-N there should be
increased levels of MLL-C in the nucleus. However the results show that MLL-N over
expression did not influence the protein levels in the nucleus, but resulted in increased
recruitment of MLL-C and a corresponding increase in H3K4Me3 marks at MLL target
gene promoters compared to the vector control.
Unlike MLL-N wt over expression; the M1585A mutation did not result in
transcriptional activation of MLL target genes. This proves that MLL PHD3 binding to
H3K4Me3 contributes to the transcriptional activation of MLL target genes. M1585A
over expression did not result in increased recruitment of MLL-C or an increase of
H3K4Me3 marks. This suggests that MLL PHD3 binding to H3K4Me3 marks recruits
more MLL-C and helps in methylation of adjacent nucleosomes leading to transcriptional
activation of MLL target genes.
The results from Cyp33 over expression experiments performed in the first aim of
this study showed a Cyp33 mediated increase in JARID1A/B demethylases at MLL target
genes and decrease in H3K4Me3 marks at MLL target gene promoters. This result
suggested a role for MLL PHD3 in protecting H3K4Me3 from demethylation. If that is
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true, then upon abrogation of MLL PHD3 binding to H3K4Me3, there should be
increased recruitment of JARID1 histone demethylases and a corresponding decrease in
H3K4Me3. However, mutating the H3K4Me3 binding site in MLL PHD3 (M1585A) did
not result in increased recruitment of JARID1B at MLL target gene promoters, while
showing decreased recruitment of MLLC and H3K4 trimethylation. This result suggest
that in MEFs (Mll+/+), MLL PHD3 binding to H3K4Me3 is mainly required for
propagation of H3K4 methyl marks to adjacent nucleosomes and not for the protection of
H3K4Me3 from JARID1B histone demethylase. Additionally, this result indicates that
there may be alternative mechanisms that contribute to Cyp33 mediated increased
recruitment of JARID1B at MLL target gene promoters other than Cyp33 reducing the
protection of H3K4Me3 by MLL PHD3.
Cyp33 is a transcriptional repressor of MLL target genes; therefore, by abrogating
Cyp33 binding to MLL PHD3, we expected a greater increase in MLL target genes
expression than MLL-N wt over expression. Over expression of M1606D mutant (that
does not bind Cyp33) resulted in increased expression of MLL target genes, but the effect
was similar to that of MLL-N wt over expression. This may be because the repressive
effects of endogenous levels of Cyp33 in the cell may be too small in comparison with
the transactivation effect of overexpression of MLL-N to be noticed in this experiment.
Additionally, over expression of the M1606D mutant resulted in decreased recruitment of
MLL-C and JARID1B when compared to MLL-N wt and M1585A at the Hoxa9
promoter. The results from the first aim of the study suggested that JARID1B is one of
the downstream effectors of Cyp33 mediated transcriptional repression of MLL target
genes. In agreement with this result, mutating the Cyp33 binding site (M1606D) in the
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MLL PHD3 resulted in decreased recruitment of JARID1B at the HOXA9 promoter.
Surprisingly, this mutation also resulted in decreased recruitment of MLL-C at the Hoxa9
promoter. Despite the decreased recruitment of MLL-C, the increase in expression of
MLL target genes upon over expression of M1606D may be explained by relief of
transcriptional repression by JARID1B. The reason for the over expression of M1606D
mutation resulting in decreased recruitment of MLL-C at the HOXA9 promoter is not
clear. Yokoyama et al., have shown that PHD1, PHD4 and FYRN and FYRC domains
are required for interaction of MLL-N and MLL-C 38. Since the MLL PHD 1, 2 and 3 are
tandem PHD fingers; the methionine to aspartate mutation in PHD3 may have an effect
on structure and function of the 3 PHD cassette unit and thus may interfere with MLL-C
recruitment by PHD1. Additionally, the targeting of proline 1629 by Cyp33 from cis-to
trans results in a drastic change in the relative positions of PHD1 and PHD4 which are
located at the opposite ends of this prolyl bond, which may contribute to the recruitment
of MLL-C by PHD-1 and PHD-4 (Figure 26) 29,38.
The Hoxa9 and Meis1 genes are expressed at higher levels in hematopoietic
progenitors and are required to keep the hematopoietic progenitors in an undifferentiated
state 106. Over expression of MLL-N wt and M1606D in hematopoietic progenitors
resulted in increased expression of MLL target genes like Hoxa9 and Meis1 and also
increased the colony formation of hematopoietic progenitors when compared to M1585A
(which does not bind H3K4Me3). This proves that MLL PHD3 binding to H3K4Me3
contributes to transcriptional activation of MLL target genes allowing the hematopoietic
progenitors to remain in undifferentiated state and form colonies.
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Figure 26: Putative model for the effect of Cyp33 binding to MLL PHD3 on
recruitment of MLL-C

The prolyl-isomerase activity of Cyp33 targets P1629 in the linker region between the
PHD3 and the bromo-domain of MLL. This cis- trans peptidyl prolyl isomerization
results in drastic change in conformation and the relative positions of PHD1 and PHD4
which are located at the opposite ends of this prolyl bond and allows Cyp33 to bind to
PHD329 . In addition to FYRN and FYRC domains of MLL; the PHD1 and PHD4 are
also required for mediating the interaction between MLL-N and MLL-C38. Abrogation of
MLL PHD3 binding to Cyp33 PHD3 (M1606D) may have an effect on the structure and
the function of the 3 PHD cassette unit and thus may interfere with MLL-C recruitment
by PHD1.
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Cdkn1b is a transcriptional target of MLL. Xia et al., have shown that the
transcriptional outcome of MLL overexpression depends on the cell type 11. Concordant
with Xia et al. results, MLLN over expression showed cell-type specific transcriptional
outcome of Cdkn1b. As mentioned earlier, MLL-N wt over expression resulted in
transcriptional activation of Cdkn1b in MEFs, whereas, there was no effect in
hematopoietic progenitors. In contrast to MLL-N wt, over expression of M1585A in
hematopoietic progenitors resulted in decreased expression of self-renewal genes like
Hoxa9 and Meis1, but showed increased expression of cell cycle inhibitors like Cdkn1b
and Cdkn1a. Furthermore, over expression of M1585A in hematopoietic progenitors
resulted in drastic reduction of colony formation. Fast proliferating cells like
hematopoietic progenitors have lower levels of Cdkn1b whereas growth arrested cells
like terminally differentiated cells have higher levels of Cdkn1b expression 109. Cdkn1a
expression increases upon induction of differentiation 109. Taken together, the decreased
expression of self-renewal genes, increased expression of cell cycle regulators and
decreased colony formation suggesting that M1585A over expression may inhibit the
proliferation and/or induce differentiation of hematopoietic progenitors.
The wild type MLL allele is required for MLL-AF9 induced leukemogenesis and
is also required for the survival and maintenance of MLL-AF9 transformed leukemic
cells. The wild type MLL is recruited to HOXA9 and Meis1 promoters and is required for
trimethylation of H3K4 at HOXA9 and Meis1 promoters, thus contributing to their
transcriptional activation in MLL-AF9 transformed leukemia cells 20. MLL fusions lack
PHD fingers. We hypothesized that MLL PHD3 (encoded in the wild type MLL allele)
binding to H3K4Me3 contributes to the transcriptional activation of MLL target genes in
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MLL-AF9 transformed cells. The results from this experiment showed that MLL-N or
mutants over expression did not have an effect on colony formation of MLL-AF9
transformed hematopoietic progenitors. The MLL fusion protein constitutively activates
the transcription of Hoxa9 and Meis1. Most common fusion partners of MLL; AF9, AF4,
ELL and ENL are present in super elongation complex (SEC) along with transcription
elongation factor like P-TEFB. The SEC is implicated in transcriptional activation of Hox
genes in MLL rearranged leukemia 110. The common fusion partners like AF-9, AF-10,
and ENL are found in complex with DOT1L, a H3K79 methyl transferase. The aberrant
recruitment of DOT1L to MLL target promoters constitutively activates the transcription
of Hoxa9 111–114. Hence the effects of MLL-N wt or mutants may be masked by the very
high levels of over expression of MLL-AF9 in mouse hematopoietic progenitors. In the
future, to determine the role of MLL PHD3 binding to H3K4Me3, we may have to
partially inhibit DOT1L in MLL-AF9 transduced hematopoietic progenitors and then
study the effects of abrogation of MLL PHD3 on leukemogenesis.
The results from the experiments performed in mouse hematopoietic progenitors
showed that MLL PHD3 binding to H3K4Me3 contributes to the transcriptional
activation of MLL target genes in hematopoietic progenitors and is required for
hematopoietic progenitor proliferation. Thus we have identified a novel biological
function for MLL PHD3 binding to H3K4Me3, this opens up many avenues for further
studies. Chromosomal amplification of MLL is frequently seen in MDS, AML, ALL, and
specifically in therapy related leukemia and is associated with poor prognosis 115–118.
Patients with MLL amplification over express the wild type allele and show increased
expression of HOXA9 and Meis1. Hence disrupting the interaction between MLL PHD3
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and H3K4ME3 in MLL amplified leukemia may be a potential treatment option 115. MLL
is haplo-insufficient, given the importance of MLL in fetal and adult differentiation,
development and cell cycle regulation, a heterozygous mutation that disrupts the binding
of MLL PHD3 to H3K4Me3 may prevent MLL from performing its functions resulting in
developmental disorders or diseases. Due to the enormous size of the MLL gene, the
mutation studies on MLL are limited. However with the advent of next generation
sequencing, it will be interesting to determine if the mutation of MLL PHD3 binding to
H3K4Me3 occurs frequently in any developmental disorders.
In summary, over expression of Cyp33 caused increased H3 density, decreased
H3Ac, increased recruitment of JARID1 histone demethylases, and decreased H3K4Me3
at MLL target gene promoters. As a consequence, Cyp33 over expression resulted in
transcription repression of MLL target genes. Abrogation of binding of H3K4Me3 in
MLL PHD3 resulted in decreased recruitment of MLL-C, decreased in H3K4Me3 levels,
decreased MLL target gene expression and decreased expansion of hematopoietic
progenitors when compared to MLL-N wt, demonstrating that MLL PHD3 binding to
H3K4Me3 contributes to the transcriptional activation of MLL target genes.
Collectively, the results from this study points us to a model wherein MLL PHD3
binding to H3K4Me3 helps MLL-C to trimethylate H3K4 on adjacent nucleosomes,
contributing to transcriptional activation of MLL target genes, as shown in the model
(Figure 27). Whereas, excess of Cyp33 results in increased recruitment of JARID1A/B at
MLL target gene promoters in a PPIase- dependent manner resulting in active
demethylation of H3K4Me3, resulting in target gene repression (Figure 28). Thus MLL
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PHD3 functions as a part of a molecular switch in transcriptional regulation of MLL
target genes.
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Figure 27: Model for the function of the MLL PHD3-H3K4Me3 interaction

MLL is recruited to its target promoters by several mechanisms. The binding of MLL
PHD3 to H3K4Me3 may be one of the mechanisms. Thus the MLL PHD3 may help
target the SET domain of MLL-C to trimethylate adjacent histones. This maintains the
H3K4Me3 marks at the target promoters leading to sustained expression of Hoxa9 and
Meis1 in hematopoietic progenitors.
Figure 28: Model for effect of excess of Cyp33 on trimethylation of H3K4 at MLL
target gene promoters

Excess of Cyp33 results in increased recruitment of JARID1 A/B histone
demethylases to MLL1 target gene promoters, resulting in decrease in H3K4Me3
marks at MLL1 target gene promoters leading to transcriptional repression of MLL1
target genes. The mechanism by which Cyp33 binding to MLL stimulates JARID1A/B
recruitment to chromatin is not known. However, the PPIase activity of Cyp33 is
required for the recruitment of JARID1B to MLL target gene promoters. JARID1B
binds DNA in a sequence specific manner, and binds H3K4Me3.
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